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Currently, there are over 5.3 million people in the United States diagnosed 
with Alzheimer’s disease, with the disease being the sixth leading cause of 
death in the country. Current drugs on the market for the treatment of 
Alzheimer’s disease are lipophilic small molecules that cross the blood-brain 
barrier by passive diffusion and none have been clinically useful in reversing 
the symptoms of the disease. Immunotherapy with intravenous 
immunoglobulin (IVIg) is one of several treatment strategies now being studied 
as part of efforts to discover safe and more effective treatment paradigms for 
Alzheimer’s disease. 
 In 2005, Weill Cornell Medical College initiated the phase I clinical trial 
of IVIg for the treatment of Alzheimer’s disease, and the clinical outcomes 
indicated improvements in the cognitive abilities of subjects beyond 
expectations. This dissertation will address combining proteomics and 
statistical approaches with novel designs for in vitro blood-brain barrier models 
with an attempt to understand the molecular basis for the disease-modifying 
effects of IVIg in Alzheimer’s disease.  
 The first part of the thesis focuses on the development of a new in vitro 
model of the blood-brain barrier based on a co-culture between primary mouse 
 brain microvascular endothelial cells and primary rat astrocytes on 
commercially available polyester membranes and nanofabricated 
poly(hydroxyl styrene) membranes. This model serves as a successful 
platform technology for evaluating molecular transport across the blood-brain 
barrier. The permeability of central nervous system drugs across this in vitro 
model correlated well with in vivo data, with the correlation coefficient being 
0.98. The second part of this thesis provides examples of proteomics 
approaches coupled with advanced statistical modeling that can be utilized to 
identify therapy induced biomarkers in the cerebrospinal fluid. Specifically, 
cerebrospinal fluid samples from Alzheimer’s subjects who underwent IVIg 
immunotherapy were analyzed using gel-based proteomics and the results 
were analyzed using a statistical model to identify 25 therapeutically relevant 
biomarkers in response to IVIg. These proteins have been previously 
implicated in Alzheimer’s disease and the changes in their concentration is 
consistent with previous reports regarding the expression of them in the brain 
of Alzheimer’s subjects compared to normal individuals.  
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 CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background and Motivation 
The development of therapeutics for the central nervous system (CNS) is one 
of the most challenging areas in drug development. This is primarily because, 
in addition to all of the other complications one faces in developing new drugs 
targeting peripheral sites, one must also consider the blood-brain barrier 
(BBB) [1-2]. Among prevalent forms of dementia, Alzheimer’s disease (AD) is 
the leading cause in the elderly and affects over 5.3 million people in the 
United States [3]. Drugs currently on the market for AD are traditionally small, 
relatively lipid-soluble compounds. These drugs cross the BBB by means of 
transmembrane diffusion and they are not very effective in penetrating deep 
into the brain tissue and treating the symptoms of AD. As a result, 
immunotherapy is one of several treatment strategies now being studied as 
part of efforts to discover safe and more effective means of treating AD [4]. 
Abundant evidence suggests that a key event in AD pathogenesis is the 
conversion of the amyloid beta (Aβ) peptide from soluble to aggregated forms 
in the brain [5-13]. Active immunization with the Aβ peptide has been shown to 
decrease brain Aβ deposition in transgenic mouse models of AD [14], and 
certain peripherally administered anti-Aβ antibodies were shown to mimic this 
effect (i.e. passive immunization) [15].  
Intravenous immunoglobulin (IVIg) is derived from the pooled 
immunoglobulins of healthy human blood donors and thus contains higher 
titers of polyclonal anti-Aβ antibodies than is typically found in the plasma of 
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 AD patients. In addition, IVIg has other effects that are potentially relevant to 
AD treatment including anti-inflammatory actions related to down-regulation of 
pro-inflammatory cytokines, blockage of the complement cascade, and an 
increase in the cerebrospinal fluid (CSF) IgG content [16]. Thus, although the 
initial rationale for the efficacy of IVIg in AD is the presence of antibodies 
against Aβ, there may exist other IVIg components that are able to cross the 
BBB and have disease-modifying effects.  
IVIg immunotherapy as it stands today, may not be a practical 
treatment strategy for AD for several reasons. First, IVIg is an expensive 
therapeutic product because the blood sera obtained from over a thousand 
individuals should go through rounds of purification, pathogen elimination, and 
sterilization. Second, since IVIg is a blood product, it is subject to blood donor 
and availability limitations. Third, it is difficult to keep the composition of IVIg 
consistent among batches due to variations in donors’ blood compositions. 
Thus, identifying therapeutically relevant biomarkers in IVIg with respect to AD 
and studying the pharmacodynamics and pharmacokinetics of these 
biomarkers can potentially lead to the identification and development of new 
drug targets that can reduce the cost of therapy, and improve the accessibility, 
quality, and consistency of care. 
Discovering a molecular mechanism for the disease-modifying effects 
of IVIg in AD can be approached in two phases. The first phase involves 
identifying therapeutically relevant IVIg protein targets in the CSF. Current 
advances in proteomics provide ample opportunities to address this issue [17-
21]. There have been a large number of studies that apply two-dimensional gel 
electrophoresis (2DE) to the study of neurologic disease for the discovery of 
biomarkers and in the understanding of mechanism in a general sense. 
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 Specifically, 2DE coupled to state-of-the-art methods in mass spectrometry 
and advanced statistical models can be used to profile changes in protein 
expression that results from therapy [17].  
The second phase involves studying the pharmacodynamics and 
pharmacokinetics of the identified target biomarkers. Since successful drug 
delivery to the central nervous system is highly dependent on the molecule’s 
physico-chemical properties and its interaction with the BBB, in vitro model 
systems of the BBB have long been used for mechanistic studies and 
permeability screens [22-28]. Therefore, an in vitro BBB model can be an 
effective platform technology for initial pharmacodynamics and 
pharmacokinetics studies. While the existing in vitro model systems of the 
BBB have answered questions about the physiological, pathological, and 
pharmacological relevance of the BBB, a new generation of models is required 
to integrate knowledge of the physical, biochemical, and transport properties 
of the BBB together with the knowledge of the cell biology [29-43]. 
 
1.2 Project Goals 
The objective of this research is two-fold: 1) To improve the utility of current in 
vitro BBB models for molecular transport studies using new biochemical and 
nanofabrication techniques, 2) To discover the therapeutic targets of the IVIg 
in CSF by analyzing samples from AD subjects who underwent IVIg 
immunotherapy, using a combination of proteomics and statistical approaches. 
 
1.3 Scope of the Work 
This dissertation is organized in two sections. Chapters 2-5 explain 
development of new techniques and technologies to build a new generation in 
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vitro model of the BBB that addresses some of the limitations associated with 
current models. This model establishes the platform for future studies of IVIg 
transport. Chapter 2 provides a brief introduction on the BBB physiology, the 
importance of BBB in neurodegenerative disorders, especially AD, and current 
in vitro models and their limitations. In vitro BBB models are either based on 
primary brain microvascular endothelial cells (BMEC) or peripheral endothelial 
cells (EC). Chapter 3 provides comprehensive data on a co-culture model 
between aortic EC and astrocytes as an attempt to bypass the labor intensive 
isolation of primary BMEC. This study found that aortic EC are not induced by 
astrocytes’ soluble factors and so are not an appropriate cell line for in vitro 
BBB models. Chapters 4 and 5 are devoted to nanofabrication techniques and 
biochemical interventions used to address some of the limitations associated 
with current BBB models, respectively. In particular establishment of mouse 
primary BMEC will be discussed. 
 Chapters 6-8 are devoted to IVIg immunotherapy in AD and its disease-
modifying effects. Chapter 6 provides an overview of IVIg immunotherapy and 
its applications in neurologic and autoimmune disorders. Furthermore, it 
proposes possible proteomics approaches to understand the disease-
modifying mechanisms of IVIg in neurologic diseases by incorporating the 
immunology network theory [44]. Chapter 7 explains a statistical analysis of 
the effects of IVIg on a panel of previously identified diagnostic biomarkers of 
AD [21]. Chapter 8 aims to provide a proteomics and statistical framework to 
identify the IVIg-induced biomarkers in the CSF of AD subjects who underwent 
immunotherapy. Additional conclusions and recommendations for future work 
are presented in Chapter 9.
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 CHAPTER 2 
 
THE BLOOD-BRAIN BARRIER  
 
2.1 The Physiology of the Blood-Brain Barrier 
The blood-brain barrier (BBB) is a unique, selective barrier formed by the 
endothelial cells (EC) that line cerebral capillaries and controls the molecular 
exchange between the blood and the brain interstitial fluid (ISF). The total 
length of brain capillaries in humans is estimated to be 650 km, with the total 
surface area between 10 – 20 m2. This architecture provides an enormous 
surface area to maximize transcellular and paracellular transport if cerebral 
capillaries behaved similar to peripheral capillaries [1].  
The EC that line these capillaries differ from those in the peripheral 
tissue in two ways. First, they have very few endocytotic vesicles, thereby 
limiting the transcellular flux. Second, they lack fenestrae and are coupled by 
tight junctions that restrict paracellular flux of water-soluble molecules [1-4]. 
This observation was first demonstrated by the German microbiologist Ehrlich 
who recognized the existence of the BBB. He observed that the central 
nervous system (CNS) was not stained by intravascular water-soluble vital 
dyes as opposed to peripheral tissue. However, the properties of the BBB are 
not exclusively due to the special cell biology of the capillary EC.  It is evident 
that perivascular elements, such as closely associated astrocytic end-feet 
processes, microglia, perivascular neurons and pericytes, further induce the 
barrier properties of these EC (Figure 2.1) [1-3].  
 The complexity of the tight junctions in cerebral capillaries is due to the 
interaction of several transmembrane proteins including occludin, the claudins, 
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Figure 2.1 | Cellular and molecular components of the BBB. A | Brain 
capillary EC and pericytes are separated from astrocytes, microglia and 
neurons by the basement membrane. B | Simplified scheme of the 
molecular composition of the brain tight junctions. Occludin and claudins 
are the most important membranous components. This figure is adapted 
by permission from Macmillan Publishers Ltd: [Nature Reviews 
Neuroscience] (3), © (2006). 
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 and the junctional adhesion molecules (JAMS). A number of cytoplasmic 
accessory proteins, including zonula occludin protein 1 (ZO-1), ZO-2, and 
cingulin link the transmembrane proteins to the actin cytoskeleton. This allows 
paracellular transport to be modulated in response to different stimuli, 
therefore making the paracellular barrier dynamic (Figure 2.1) [5-6]. The tight 
junctions significantly restrict even the movement of small ions such as Na+ 
and Cl-, so that the transendothelial electrical resistance (TEER), which is 
typically 2–20 (Ω × cm2) in peripheral capillaries, can be >1,000 (Ω × cm2) in 
brain endothelium. Because the tight junctions make the brain inaccessible to 
water-soluble (polar) molecules, they are transferred by special transporters 
[7-9]. Examples of transporters include those for glucose, neutral amino acids, 
vitamins, and nucleosides (Figure 2.2). In addition, intracellular and 
extracellular enzymes regulate the metabolic activity at the BBB such as 
monoamine oxidase (MAO), γ-glutamyl transpeptidase (γ-GTP), alkaline 
phosphatase, specific peptidases, and nucleotidases [10-11]. 
 It has been clear from the earliest histological studies that brain 
capillaries are surrounded by, or closely associated with, several cell types, 
and the influence of this microenvironment is believed to play a major role in 
inducing the capillary EC [12-13]. Structurally, the cell closest to brain capillary 
EC are the astrocytes and their foot processes cover much of the capillary’s 
basal surface [14]. In 1987, Janzer et al. [15] investigated the notion that 
astrocytes might induce EC to adapt a brain like phenotype. They cultured rat 
astrocytes obtained from neonatal brain and transplanted them into a chick 
eye chamber and further assessed the barrier properties of the EC using 
cationic dyes that mark albumin flux. The results indicated that rat astrocytes 
are capable of causing chick peripheral EC to become less permeable to large
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Figure 2.2 | Pathways across the BBB. The tight junctions severely restrict 
penetration of water-soluble compounds. However, lipid soluble molecules can freely 
diffuse across the lipid bilayer if they are smaller than 400 Da. The majority of 
molecules, including nutrients are transported actively. It is believed that larger 
proteins such as albumin and immunoglobulins are transported by adsorptive 
transcytosis. This figure is adapted by permission from Macmillan Publishers 
Ltd: [Nature Reviews Neuroscience] (3), © (2006). 
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 molecules.  
 
2.2 The Role of BBB in Alzheimer’s Disease 
BBB breakdown due to disruption of tight junctions, altered transport of 
molecules between blood and brain, aberrant angiogenesis, vessel regression, 
and inflammatory responses may initiate and/or contribute to a “vicious circle” 
of the disease process resulting in progressive synaptic and neuronal 
dysfunction and loss in disorders such as Alzheimer’s disease, Parkinson’s 
disease, amyotrophic lateral sclerosis, multiple sclerosis and others [12]. 
 Alzheimer’s disease (AD) is characterized by a progressive cognitive 
decline associated with neurovascular dysfunction, accumulation of neurotoxic 
amyloid beta (Aβ) on blood vessels and in the brain parenchyma, and 
intraneuronal lesions, or neurofibrillar tangles [16-24]. According to Figure 2.3, 
changes in the expression of key vascular genes and receptors in brain 
capillaries and small cerebral arteries may compromise (directly or indirectly) 
several BBB functions. This compromise, in turn, leads to reductions in the 
resting cerebral blood flow (CBF) and attenuated CBF responses to brain 
activation, accumulation of Aβ, and a neuroinflammatory response resulting in 
BBB breakdown. In an early disease phase, faulty clearance of Aβ at the BBB 
may favor accumulation of neurotoxic Aβ oligomers in the brain ISF. Aβ 
oligomers and focal reductions in the capillary blood flow can affect synaptic 
transmission, cause neuronal injury, and initiate recruitment of microglia from 
the blood or within the brain. At an early symptomatic stage, the BBB starts 
losing properties of an Aβ clearing membrane, and the activated endothelium 
secretes proinflammatory cytokines and CBF suppressors. This secretion  
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Figure 2.3 | Involvement of the neurovascular unit in the pathogenesis of 
AD. This figure is reprinted from [12] © (2008), with permission from Elsevier. 
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 results in a more pronounced synaptic dysfunction, accumulation of 
intraneuronal tangles, and activation of microglia leading to the activation of 
immunoglobulins. At a late symptomatic stage, the capillary unit is distorted 
with the degenerated endothelial barrier. There is a severe loss of Aβ clearing 
capability, resulting in amyloid formation on the outer side of the capillary 
membrane, an increased number of neurofibrillary tangles, and an increased 
number of activated microglia and astrocytes. At the final stage, the capillary 
unit disappears under the amyloid deposits coupled with synaptic and 
neuronal loss. 
 
2.3 Static In vitro Models of the BBB 
Designing in vitro BBB models are important for two reasons. First, the BBB 
plays an important physiological role in a number of pathologies (i.e. stroke, 
traumatic injury, brain tumors, multiple sclerosis, AIDS dementia, Parkinson’s 
disease, and AD) and the models provide an opportunity to identify the key 
factors that contribute to normal and pathological BBB [12,25]. Second, 
models help to predict drug permeability prior to animal studies due to inherent 
difficulties in performing molecular level studies on the BBB in vivo [1]. 
 Several static in vitro models of the BBB have been developed with the 
aim to better understand the cell biology of the BBB and/or to predict potential 
therapeutic permeability into the brain [26-40]. Most of these models consist of 
a monolayer of endothelial cells, often isolated from brain capillaries (BMEC) 
or peripheral capillaries, grown on the top side of a polymeric membrane 
affixed to a cylindrical plastic insert (i.e. culture Transwell®). These 
microporous membranes are either made of polyester (partially transparent) or 
polycarbonate (translucent). They are 20 – 40 µm thick depending on the 
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 manufacturer, and their pore diameter is either 0.4 µm, 1.0 µm, or 3.0 µm with 
their nominal pore density being 4×106 (polyester) and 1×108 (polycarbonate) 
pores/cm2.  
This insert is placed into a multi-well culture plate, dividing the well into 
luminal and abluminal chambers. Furthermore, to recreate the brain 
microenvironment, astrocytes or pericytes are cultured in the abluminal 
chamber to create co-cultures, or the brain EC are cultured in astrocyte 
conditioned medium [27-29,31-39]. The co-cultures are either contact co-
cultures, where astrocytes or pericytes are directly seeded on the opposite 
side of the microporous membrane, or non-contact co-cultures where the glial 
cells are seeded on the multi-well culture plate (Figure 2.4). Finally, the barrier 
properties of the model are usually assessed by one or more of the following 
techniques: transendothelial electrical resistance (TEER) measurements, 
direct determination of molecular permeability coefficients, 
immunocytochemical characterization of tight junction proteins, and assessing 
the expression level of mRNA and proteins that are highly expressed at the 
BBB (P-glycoprotein, glucose transporter-1, γ-GTP). 
 
2.4 Physical and Biological Limitations of Current Static BBB Models 
As mentioned in Sections 2.1 and 2.3, because astrocyte foot processes 
surround the brain capillaries, many in vitro models have focused on 
recreating the brain microenvironment by incorporating astrocyte conditioned-
medium or astrocyte contact or non-contact co-cultures. The purpose of 
creating the contact co-culture is to mimic the BBB anatomy by providing the 
astrocyte foot processes the opportunity to reach through the pores of the 
membrane and physically contact endothelial cells on the opposite side.  
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Figure 2.4 | Transwell® culture systems. Contact co-culture (left) and non-
contact co-culture (right). The top compartment represents the luminal (blood) 
side and the bottom represents the abluminal (brain) side. BMEC stands for 
brain microvascular endothelial cells. 
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A key drawback of the commercial microporous membrane is the 
limited number of pore sizes, the low total porosity, and the relatively thick 
membrane. Furthermore, the process of fabrication of these membranes 
results in a random distribution in the size and placement of pores, and more 
importantly the resulting diffusion path is tortuous causing entrapment of 
biomolecules [41-42]. These characteristics and the relatively large thickness 
of the membrane may hinder cell to cell contact in co-cultures or the passage 
of soluble factors through the pores [42-43]. 
 Furthermore, the majority of current in vitro models of the BBB are 
either based on immortalized brain EC or primary BMEC obtained from rat, 
bovine, or porcine. Use of such models may not be suitable for studies of BBB 
in brain cancer, neurodegenerative disorders, and inflammatory events 
involving the CNS because these diseases are generally studied in mouse 
models and thus an in vitro BBB model based on mouse BMEC may be more 
authentic and serve as a better surrogate to correlate with the in vivo studies 
[12,25]. 
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 CHAPTER 3 
 
THE EFFECT OF ASTROCYTES ON THE INDUCTION OF BARRIER 
PROPERTIES IN AORTIC ENDOTHELIAL CELLS 
 
3.1 Preface 
This chapter is adapted from: Shayan, G., Shuler, M. L., Lee, K. H., 2009. The 
effect of astrocytes on the induction of barrier properties in aortic endothelial 
cells. Biotechnology Progress, submitted. It explores the possibility of using 
bovine aortic endothelial cells in co-culture with astrocytes to create an in vitro 
model of the blood-brain barrier. 
 
3.2 Abstract 
The establishment of a primary culture of brain microvascular endothelial cells 
(BMEC) for the construction of in vitro models of the blood-brain barrier (BBB) 
is difficult and time intensive in part due to a lack of culture purity, low yields, 
and cellular de-differentiation after the first passage. This problem has created 
interest in the substitution of BMEC with immortalized brain endothelial cells 
(EC), or peripheral EC such as bovine aortic EC (BAEC). These cultures are 
easier to establish, provide higher yields, and can be passaged. Many BBB 
models have focused on further inducing the brain and peripheral EC by 
incorporating astrocyte contact or non-contact co-cultures. However, previous 
studies demonstrating induction effects of astrocyte on BAEC in contact co-
cultures, failed to recognize the extensive barrier properties of astrocytes 
alone, which can have a significant effect on interpreting the results. This 
manuscript reports the establishment of a contact and non-contact co-culture 
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 between astrocytes and BAEC or BMEC (as a control) with primary focus on 
the properties of astrocytes alone and with an enhanced statistical 
methodology to interpret the results. Transendothelial electrical resistance 
(TEER) and permeability studies revealed that astrocytes can significantly 
increase the barrier tightening of BMEC, while having no effect on BAEC. 
Immunocytochemical studies also revealed the reorganization of BMEC 
occludin junctions in the presence of astrocytes, while indicating the absence 
of this junction protein in BAEC.  In contrast to a previous report, here the 
statistical analysis revealed that observed decreases in permeability of BAEC 
in contact co-cultures is due to the addition of astrocytes’ properties in series 
and not due to induction. 
 
3.3 Introduction 
Endothelium, comprising the single cell lining of all blood and lymph vessels, 
plays a variety of crucial roles in the cardiovascular system. The endothelium 
of different tissues however have further specialized functions. For instance, in 
the brain the endothelial cells (EC) that line the cerebral vasculature provide 
an important barrier (the blood-brain barrier, BBB) for protecting the brain from 
fluctuations in plasma composition [1].  Early studies have shown that the 
brain microenvironment plays a critical role in the differentiation of capillary 
EC. The close cell-cell associations between capillary EC and astrocytes in 
particular led to the suggestion that they could mediate specific features of the 
BBB phenotype [2]. 
 Several in vitro models of the BBB have been developed to better 
understand the underlying cell biology, to predict drug permeability prior to 
animal studies, and to overcome the inherent difficulty in performing BBB 
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 molecular level studies in vivo [3]. These in vitro models [4-12] serve as 
successful surrogates to in vivo experiments and provide a critical framework 
for BBB studies. Over time, these models have been updated and refined to 
improve their utility. These updates include improved techniques to isolate 
brain microvascular endothelial cells (BMEC) [6,10,12], and induction of 
BMEC with astrocytes or biochemical agents [4,7-11]. Despite these 
advances, a comparison of experimental results within the many published in 
vitro  models remains a challenge because of differences with respect to 
cellular isolation procedures, culture configurations (mono/co-culture), the cell 
type used (origin and species), and model assessment techniques [13]. 
 Many in vitro models are based on the isolation and culture of brain EC. 
However, the establishment of a primary culture of BMEC devoid of other 
brain contaminating cells (i.e. neurons, pericytes, and microglia) is difficult and 
time intensive, and depending on the source of brain (murine, rat, porcine, 
etc.) yields can be very low [13]. Furthermore, once BMEC are cultured in 
vitro, cellular de-differentiation results in a loss of many of the functions and 
markers observed in vivo thus limiting the use of cells to passages 0 -1 [4,14]. 
Although recently a few studies have successfully proposed new biochemical 
techniques to establish pure and functional cultures of BMEC [4,10,15], there 
still exists considerable interest in the substitution of BMEC with either 
immortalized brain EC, or peripheral EC such as human umbilical vein EC or 
bovine aortic EC (BAEC), because it is easier to obtain high yields, culture, 
and passage these cells [5,16-18]. 
 Structurally, the cell type closest to brain capillary EC is the astrocyte 
and their processes form end-feet that collectively surround cerebral 
microvessels [5,7,9,18-20]. As a result, several models have focused on 
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 recreating the brain microenvironment by incorporating astrocyte co-cultures, 
or astrocyte conditioned-medium to further induce BMEC, immortalized brain 
and peripheral EC. Traditionally, many models involve a contact, or often a 
non-contact, co-culture between EC and astrocytes on commercially available 
microporous filters. Furthermore, rat or bovine BMEC co-cultured with rat 
astrocytes were shown to have higher transendothelial electrical resistance 
(TEER) and lower permeability compared to BMEC cultures alone [5,7-10,12]. 
However, in the case of BAEC, conclusive studies on the properties of 
astrocytes alone and in co-culture is limited. Therefore, it is difficult to assess 
whether the improved barrier properties in contact co-cultures is due to 
induction of EC, or is due to the summation of the properties of these two cell 
lines individually. 
 The work presented here primarily emphasizes the properties of rat 
primary astrocytes alone and uses contact and non-contact co-cultures 
between BAEC and rat primary astrocytes to more accurately examine 
possible induction effects of astrocytes on this non-neuronal EC. With this new 
emphasis, we evaluated more accurately whether there is synergy in co-
culture TEER and permeability. The results indicated that astrocytes’ ability to 
grow in multiple layers can significantly affect TEER and permeability 
measurements in contact co-cultures. The linear contrast statistical analysis 
revealed that decrease in permeability across BAEC contact co-culture is due 
to the addition of astrocytes’ resistance in series. The results also indicated 
that while BMEC recognizes the induction factors released by astrocytes in 
non-contact co-cultures, BAEC fails to do so. 
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 3.4 Materials and Methods 
3.4.1 Chemicals and Supplies 
Poly-D-lysine and L-glutamine were purchased from Fisher Scientific 
(Pittsburg, PA, USA). Human fibronectin was purchased from Millipore 
(Billerica, MA, USA). Twelve and twenty four well Transwell® permeable 
support (polyester; thickness, 10 μm; pore size, 0.4 μm; pore density, 4x106 
pores/cm2) was purchased from Corning (Lowell, MA, USA). EGM® MV and 
trypsin-EDTA were purchased from Lonza (Basel, Switzerland). Fetal bovine 
serum (FBS), Dulbecco’s Modified Eagle Medium (DMEM, with l-glutamin, 
sodium pyruvate, and low glucose), Ham’s F-12 nutrient mixture, and 
Penicillin-Streptomycin-Amphotercin (PSA) were purchased from Invitrogen 
(Carlsbad, CA, USA). Dulbecco’s phosphate buffered saline (DPBS, without 
CaCl2 and MgCl2), gentamicin, HEPES sodium salt, fluorescein sodium salt, 
Heparin, bovine serum albumin, puromycin, hydrocortisone, collagen type IV, 
Triton X-100, and goat serum were purchased from Sigma (St. Louis, MO, 
USA). Percoll was purchased from Amersham Biosciences (Piscataway, NJ, 
USA). Type II collagenase and DNase I were purchased from Worthington 
Biochemical Corp. (Lakewood, NJ, USA). Collagenase-dispase and basic 
fibroblast growth factor were purchased from Roche Molecular Biochemicals 
(Indianapolis, IN, USA). Paraformaldehyde (16%) was purchased from 
Electron Microscopy Sciences (Ft. Washington, PA, USA). Acetylated low 
density lipoprotein labeled with 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindo-
carbocyanine percholorate (DiI-Ac-LDL) and bovine platelet-poor plasma-
derived serum were purchased from Biomedical Technologies (Stoughton, 
MA, USA). Polyclonal rabbit anti-glial fibrillary acidic protein (18-0063) 
antibody, rabbit anti-occludin (71-1500) antibody, Alexa Fluor® 488 goat anti-
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 rabbit IgG antibody (A11008), and 4’,6-diamidino-2-phenylindole (DAPI) 
dihydrochloride nuclear stain were also purchased from Invitrogen (Carlsbad, 
CA, USA). Vectashield mounting medium was purchased from Vector 
Laboratories (Burlingame, CA, USA). EVOM voltohmmeter (STX2) was 
purchased from World Precision Instruments (Sarasota, FL, USA). 
 
3.4.2 Isolation of Rat Astrocytes 
Astrocytes isolated from 3 days old Wistar rat pups were provided by Dr. W. 
Shain (Wadsworth Center, Albany, NY) following established techniques [21]. 
Cells were maintained in DMEM (low glucose, with L-glutamine and sodium 
pyruvate) supplemented with 5% FBS and gentamicin at the supplier’s 
recommended concentration. Cells were grown on 75 cm2 tissue culture flasks 
at passage 0 and were fed every 3 days by completely replacing the medium. 
Cultures were maintained in a 37°C humidified cell culture incubator with 5% 
CO2.  
 
3.4.3 Bovine Aortic Endothelial Cells (BAEC) 
Cryopreserved, single donor, bovine aortic endothelial cells were purchased 
from Lonza (Basel, Switzerland) at passage 1. Cells were thawed, maintained, 
and sub-cultured according to the supplier’s recommendations. Briefly, cells 
were maintained in endothelial basal medium supplemented with bovine brain 
extract, heparin, human epidermal growth factor, hydrocortisone, gentamicin-
amphotericin, and 10% fetal bovine serum (EGM® MV). Cells were grown on 
25 cm2 tissue culture flasks and used at passage 1-6 for experiments. 
Cultures were maintained in a 37°C humidified cell culture incubator with 5% 
CO2.  
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 3.4.4 Isolation of Murine Brain Microvascular Endothelial Cells (BMEC) 
Isolation of murine BMEC was based on a modified protocol [4,11]. All animals 
were treated according to protocols evaluated and approved by the ethical 
committee of Cornell University. In summary, 10 adult female mice (B6CByF1) 
were euthanized under CO2. Forebrains were collected and stored in DMEM 
on ice. The remainder of the isolation took place under aseptic conditions. The 
brains were cut sagittally into two haves and rolled on Whatman 3MM 
chromatography paper to remove the meninges. The cortices were dissected 
away and much of the white matter was removed. The cortices were smashed 
with forceps and completely triturated and digested with 0.65 mg/mL type II 
collagenase and 37.6 U/mL DNase I in DMEM for 1 hour in 37°C shaker (250 
rpm). The enzyme solution was then diluted in DMEM and centrifuged at 1000 
g  for 8 minutes. To remove myelin the pellet was re-suspended in 20% (w/v) 
bovine serum albumin in DMEM and centrifuged at 1000 g for 20 minutes. The 
pellet was re-suspended and further digested with 0.69 mg/mL collagenase-
dispase and 28.3 U/mL DNase I in DMEM for 1 hour in 37°C shaker (200 
rpm). The microvessels were separated on a 33% continuous Percoll gradient, 
collected and plated in a 35mm petri-dish coated with collagen type IV and 
fibronectin. Cultures were maintained in DMEM supplemented with 4 µg/mL 
puromycin, 20% bovine platelet-poor plasma-derived serum, 1 ng/mL human 
basic fibroblast growth factor, 1 µg/mL heparin, 2 mM L-glutamine, and an 
antibiotic solution (100 U/mL penicillin, 100 µg/mL streptomycin, and 0.25 
µg/mL amphotericin). Culture medium was completely replaced every day, 
and puromycin was removed from the medium on day 3. Cells were 
subcultured on day 3.5 and seeded on transwells coated with collagen type IV 
and fibronectin at 300,000 cells/cm2.  Cultures were maintained in Ham’s F-
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 12:DMEM  (1:1) supplemented with 2 mM L-glutamine, 550 nM 
hydrocortisone, and an antibiotic solution (100 U/mL penicillin, 100 µg/mL 
streptomycin, and 0.25 µg/mL amphotericin). Cultures were maintained in a 
37°C humidified cell culture incubator with 5% CO2.  
 
3.4.5 Co-Culture Setup 
For the BAEC study, two different models were created each including two 
types of co-cultures (contact and non-contact) (Figure 3.1). In model 1, BAEC 
were seeded 8 hours post astrocyte seeding; whereas in model 2, BAEC were 
seeded 3 days post astrocyte seeding. Model 2 was also replicated using 
murine BMEC as a control.  
 For better astrocyte attachment, the backside of the transwell or the 
bottom of the multi-well dish was treated with 5 μg/cm2 of poly-D-lysine in 
DMEM without serum for one hour in the culture incubator. Before use, poly-D-
lysine was aspirated and the surface was rinsed once with DPBS. Astrocytes 
(passage 1) were seeded at 10,000 cells/cm2 either on the bottom of the dish 
(non-contact co-culture) or on the backside of the transwell (contact co-
culture). For contact co-cultures, an in-house multi-well dish with deeper wells 
(Figure 3.2) was designed and fabricated. With this device, the transwell can 
be inverted inside the well without the membrane coming in contact with the 
lid, thus allowing for a longer time for astrocytes to attach with medium around 
the transwell. After 8 hours, all transwells were inverted inside a regular 12-
well or 24-well culture dish containing DMEM supplemented with 5% FBS in 
the bottom compartment. If the top compartment was to be seeded with BAEC 
immediately (model 1), it was seeded at 84,000 cells/cm2 (passage 5) in 
EGM® MV. In model 2, the top compartment was filled with EGM® MV or 
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Figure 3.1 | Schematic of two different BBB models. (A-C) shows the 
contact co-culture. Astrocytes were seeded on the backside of the membrane 
for 2 hrs while the transwell was inverted inside the multi-well dish. The 
transwell was then placed inside a regular multi-well dish for 8 hrs after which 
BAEC was added (model 1). In Model 2, BAEC or BMEC was added 3 days 
after the attachment of astrocytes. (D-E) shows that non-contact co-culture 
with the same culture conditions as the contact co-culture. 
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Figure 3.2 | Design of the in-house multi-well dish. The multi-well dish 
provides significant head space above the transwell which facilitates astrocyte 
attachment and culture. 
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 BMEC medium (Ham’s F-12:DMEM  (1:1) supplemented with 2 mM L-
glutamine, 550 nM hydrocortisone, and an antibiotic solution) until day 3 when 
BAEC (passage 6) or murine BMEC were seeded as described above. 
Controls included empty transwell with the top-side of the membrane coated 
with collagen type IV and fibronectin and bottom-side coated with poly-D-
lysine, BAEC only (in EGM® MV), murine BMEC only (in BMEC medium), and 
astrocyte only transwells. Culture medium in both compartments was replaced 
completely every 3 days. 
 
3.4.6 Transendothelial Electrical Resistance Measurements  
Transendothelial electrical resistance (TEER) was measured using an EVOM 
voltohmmeter (STX2) on days 2 and 3 following establishment of co-culture. 
Final resistance (Ω x cm2) was calculated after subtracting the resistance of an 
empty filter. In the case of contact co-cultures, the resistance of astrocytes 
were also subtracted from the total resistance by the means of linear contrast 
analysis [22]. Three TEER measurements were made for each transwell at 
each time point and the arithmetic mean calculated. TEER measurements of 
three transwells for each culture condition were used to compute the mean 
and standard deviations reported.  
 
3.4.7 Fluorescein Sodium Permeability Measurements 
Prior to permeability studies, culture media from the top and bottom 
compartments was replaced with pre-equilibrated transport buffer (10 mM 
HEPES, 0.1% w/v bovine serum albumin, 4.5% w/v glucose). A solution of 
sodium fluorescein (376 Da) in transport buffer was then added to the upper 
compartment of the transwell to yield a final concentration of 1 μM. Two 
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 hundred microliter aliquots were removed from the bottom compartment and 
the volume replaced with pre-equilibrated transport buffer every fifteen 
minutes over 60 minutes. Based on the rate of influx of sodium fluorescein into 
the bottom compartment, permeability coefficients were calculated [6]. 
 
3.4.8 Uptake of DiI-Ac-LDL 
DiI-Ac-LDL was diluted to 10 μg/mL in EGM® MV or BMEC medium and 
added to the upper compartment containing BAEC or BMEC prior to other 
immunofluorescent studies. The cells were then incubated in a 37°C 
humidified cell culture incubator with 5% CO2 for 4 hours. The cells were 
rinsed three times with DPBS and then fixed in 4% (w/v) paraformaldehyde at 
room temperature for 20 minutes.  
 
3.4.9 Immunocytochemistry 
All cultures were rinsed twice with DPBS followed by fixation in 4% 
paraformaldehyde for 20 minutes (all steps performed at room temperature 
unless stated otherwise). Following three 5 minute rinses in DPBS, astrocytes 
were permeabilized with 0.1% Triton X-100 in DPBS for 15 minutes, and 
BAEC or BMEC were permeabilized with 0.05% Triton X-100 for 5 minutes on 
ice. (BAEC and BMEC were also pre-permeabilized with 0.2% Triton X-100 for 
2 minutes on ice if staining for occludin). After three 5 minute rinses in DPBS 
following permeabilization, astrocytes and EC were blocked in 10% goat 
serum in DPBS for 15 and 7 minutes, respectively. All subsequent steps were 
performed on a shaker. The following concentrations in 10% goat serum were 
used for primary antibodies:  rabbit anti-GFAP 4 µg/mL, and rabbit anti-
occludin 15 µg/mL. Primary antibodies were added to the appropriate 
37 
 compartment for 1 hour followed by three 10 minutes rinses in 1% goat serum. 
Cells were incubated for 1 hour in 1:500 dilution of Alexa Fluor® 488 goat anti-
rabbit IgG antibody followed by three 10 minutes rinses in 1% goat serum. 
DAPI was added in 300 nM for 3 minutes prior to mounting the membrane on 
a glass slide with a cover slip in Vectashield mounting medium. Samples were 
observed in a Leica SP2 scanning confocal misroscope (Leica Microsystems 
Inc., Bannockburn, IL, USA). 
 Control samples were treated exactly as stated above, except that the 
primary antibodies were replaced with a rabbit IgG fraction negative control. A 
secondary antibody-only control was also included. 
 
3.4.10 Statistical Analysis  
The statistical analysis was carried out using JMP® 7.0 (SAS Institute Inc., 
Cary, NC, USA). Statistical evaluation of the resistance and permeability data 
was performed using a least square linear regression model. All results are 
mean ± standard deviation (SD). 
 One-way analysis of variance (ANOVA) was used to evaluate the effect 
of cultivation period on the resistance of astrocytes and BAEC alone. The 
influence of astrocytes on the resistance and permeability of BAEC and BMEC 
in contact and non-contact co-cultures was also evaluated using one-way 
ANOVA with linear contrast. If the effect of any factor was significant, pair-wise 
comparisons were made using the Tukey honestly significant difference (HSD) 
test. The global risk was fixed at p < 0.05 for all tests. 
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 3.5 Results 
3.5.1 Effect of Cultivation Period on TEER of Astrocytes and BAEC 
Before establishing the co-cultures, two separate experiments were performed 
to evaluate the changes in the resistance of astrocytes seeded on the 
backside of polyester transwells over time, as well as BAEC resistance 
seeded in the top compartment of the transwell. TEER was monitored starting 
on day 2 until a significant reduction was observed (Figure 3.3). TEER of 
BAEC significantly increased on day 3 followed by a significant reduction on 
day 4. TEER of astrocytes significantly increased on day 7 followed by a 
significant reduction on day 9. 
 
3.5.2 Effect of Astrocytes on TEER of BAEC and Murine BMEC 
Two different models, each including two types of co-cultures (contact and 
non-contact) (Figure 3.1, Figure 3.2) were created based on the TEER results 
from the previous experiment. The purpose of creating two models was to 
evaluate whether the age of astrocytes, and thus the concentration of 
astrocytes’ soluble factors as well as their peak TEER,  in both contact and 
non-contact co-culture has a significant effect on induction of BAEC. 
 TEER results from model 1 (Figure 3.4 A) illustrate that on day 3 when 
BAEC reach their peak TEER (20.3 ± 7.7 Ω×cm2), the resistance of the 
contact and non-contact co-cultures are significantly less than the resistance 
of BAEC alone (1.8 ± 7.7 ; 4.2 ± 7.7 Ω×cm2), suggesting that astrocytes 
reduce the resistance of BAEC if both cells are seeded within a few hours of 
each other. On the other hand in model 2, when BAEC are seeded 3 days 
after astrocytes (i.e. both cell types reaching their peak TEER concurrently), 
the resistance of the non-contact co-culture (25.7 ± 3.2 Ω×cm2) is statistically 
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Figure 3.3 | TEER of BAEC (A) and astrocytes (B) over time. TEER was 
monitored starting one day after culture establishment and continued until a 
significant reduction was observed. Data is representative of two independent 
experiments. Results are the means ± SD of three transwells with three 
measurements each in three independent experiments. Statistical analysis of 
the data was performed by one-way ANOVA followed by Tukey honestly 
significant difference test which revealed significant differences (p < 0.05) on 
day 3 (A) and day 7(B). Star represents statistical significance. 
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Figure 3.4 | TEER of model 1 (A) and model 2 with BAEC (B) or BMEC 
(C). TEER was monitored on second and third day after EC culture 
establishment in both models. (A) In model 1 when both cell lines are 
seeded within 8 hrs of each other, TEER of contact (BAEC/Astro) and non-
contact (BAEC-Astro) co-cultures are significantly less than TEER of BAEC 
alone on day 2 and 3. (B) In model 2 when BAEC is seeded 3 days after 
astrocyte culture establishment and both cells reach their peak resistance 
on day 3, TEER of contact and non-contact co-cultures are equal to TEER 
of BAEC alone. (C) In model 2, when murine BMEC is seeded 3 days after 
astrocyte culture establishment, TEER of contact co-culture is the same as 
BMEC alone while TEER of the non-contact co-culture increases 167% 
compared to BMEC alone. TEER in (A) and (B) is expressed as a 
normalized % of the BAEC on day 2, and in (C) as a normalized % of the 
BMEC on day 2. Results are the means ± SD of three transwells with three 
measurements each in three independent experiments. Statistical analysis 
of the data was performed by one-way ANOVA (p < 0.05) along with linear 
contrast analysis for contact co-cultures. Star represents statistical 
significance. 
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 the same as BAEC alone (33.1 ± 5.1 Ω×cm2) and the resistance of the contact 
co-culture (30.6 ± 9.1 Ω×cm2) is not higher than the sum of the resistances of 
BAEC and astrocytes individually (Figure 3.4 B).  However, when model 2 was 
replicated with murine BMEC (Figure 3.4 C), the resistance of the non-contact 
co-culture (107.8 ± 3.1 Ω×cm2) was 167% higher than the BMEC alone (78.9 ± 
7.4 Ω×cm2) indicating induction by astrocytes while the resistance of the 
contact co-culture (72.1 ± 3.9 Ω×cm2) was similar to BMEC alone. 
 
3.5.3 Effect of Astrocytes on Permeability of BAEC and Murine BMEC 
In both models, permeability of the endothelial layer was monitored by 
measuring the influx rate of sodium fluorescein from the top compartment of 
the transwell to the bottom. Representative influx rates over the transwell 
membrane area correspond to the permeability coefficient for each 
configuration . In both models, statistical analysis of the data revealed no 
significant difference between the permeability of BAEC alone (1.9 ± 0.26 10-5 
cm/s) and non-contact co-cultures (1.92 ± 0.26 10-5 cm/s). However, in model 
2 with murine BMEC, the permeability of the non-contact co-culture (0.62 ± 
0.03 10-5 cm/s) decreased significantly compared to the BMEC alone (0.78 ± 
0.008 10-5 cm/s). Linear contrast analysis revealed no significant difference 
between the permeability of contact co-cultures (0.696 ± 0.16; 0.54 ± 0.15 10-5 
cm/s) and the sum of permeabilities of BAEC or BMEC and astrocytes (2.5 ± 
0.45 10-5 cm/s) individually. Results are the means ± SD of three transwells 
with three measurements each in three independent experiments. 
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 3.5.4 Immunocytochemical Characterization of BAEC, Murine BMEC, and 
Astrcoytes 
BAEC cultured alone or in the presence of astrocytes displayed a 
characteristic cobblestone-like appearance upon reaching confluence (Figure 
3.5 A), while BMEC displayed characteristic spindle shaped morphology 
(Figure 3.5 C). The BAEC and BMEC cultures in both models retained their 
phenotype as judged by the uptake of DiI-Ac-LDL (Figure 3.5 B, D) with the 
level of staining being higher in BMEC. Astrocytes cultured on the bottom side 
of the transwell as well as in the multi-well dish, attached and proliferated well 
and retained their phenotype as judged by GFAP antibody staining (Figure 3.5 
E). BAEC alone or in co-culture failed to stain positive for occludin (Figure 3.6 
B), indicating the presence of none or very few tight junctions. However, 
BMEC stained positive for occludin (Figure 3.6 A) and interestingly the 
patterns of staining in contact co-culture (Figure 3.6 C) and non-contact co-
culture (Figure 3.6 D) differed from BMEC alone culture. This confirms the 
ability of astrocytes to affect BMEC. 
 
3.6 Discussion 
For the first time, a complete analysis of TEER, permeability, and 
immunocytochemistry results on contact and non-contact co-cultures of rat 
astrocytes and BAEC is provided. In contrast to a previous study [17] reporting 
that rat astrocytes can induce BBB properties in contact co-cultures with 
BAEC, we report here on the inability of BAEC to acquire BBB properties in 
contact and non-contact co-cultures based on study of TEER and permeability 
of astrocytes alone and linear contrast statistics. Immunocytochemical 
characterization also indicated minimum expression of junction protein 
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Figure 3.5 | Immunocytochemical characterization of EC and Astrocytes. 
(A,C) Phase contrast image of BAEC (A) and BMEC (C) in transwell. (B,D) 
Immunofluorescent confocal images of BAEC (B) and BMEC (D) probed for 
uptake of DiI-Ac-LDL. (E) Immunofluorescent confocal image of astrocytes 
probed for glial fibrillary acidic protein (GFAP). (F) Immunofluorescent confocal 
image of contact co-culture probed for uptake of DiI-Ac-LDL and GFAP. Scale 
bars represent 50 μm. 
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Figure 3.6 | Immunocytochemistry of occludin in BAEC and BMEC. (A-B) 
Confocal image of BMEC (A) and BAEC (B) stained for occludin. (C-D) 
Confocal image of BMEC in contact (C) and non-contact (D) co-culture with 
astrocytes stained for occludin. Scale bars represent 50 μm. 
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 occludin, which is an essential component for making tight EC barriers. These 
results serve as a complement to previous studies reporting zero or very low 
activities of alkaline phosphatase and γ-glutamyl transpeptidase in BAEC, both 
of which are up-regulated markers in BMEC and important in in vitro BBB 
models [5,23]. 
The ability to use rat primary astrocytes to induce rat and bovine BMEC 
to make tighter junctions in vitro is well documented in the literature [5,7-
10,12,18]. This induction appears to be due to both astrocytes’ soluble factors, 
as evident in non-contact co-culture models or those that employ astrocyte 
conditioned-medium, and astrocytes’ physical contact with EC, as evident in 
contact co-culture models [5,7,9,24]. These studies also show that induction 
seems to be independent of the species of origin of astrocytes and BMEC, 
meaning that rat astrocytes not only induce rat BMEC, but also bovine BMEC. 
Here, we have shown for the first time that rat astrocytes can also induce 
murine BMEC in non-contact co-cultures. This control study with murine 
BMEC, and previous studies with bovine BMEC, indicated positive induction 
by rat astrocytes. Thus, it seems plausible  that the lack of BAEC induction is a 
result of the inability of this peripheral EC (i.e. aortic EC) to recognize the 
induction factors released by astrocytes in vitro, and not a result of the 
heterologous nature of this co-culture. Although Janzer and Raff (1987) 
provided direct evidence that astrocytes are capable of inducing BBB 
properties in non-neuronal EC (capillaries of the anterior eye chamber) in vivo, 
our study suggests that care must be taken in applying this conclusion to in 
vitro studies.  
In contrast to the previous report [17], this study evaluated the TEER 
and permeability of the contact co-cultures based on linear contrast statistics. 
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 The previous report [17] failed to subtract the resistance of astrocytes alone 
culture from contact co-culture results. These measurements help ensure that 
any change in the TEER and permeability of the contact co-culture is not a 
result of the addition of astrocytes’ and BAEC/BMEC resistance in series, but 
a result of induction. In the case of BMEC cultures, the use of puromycin 
provides higher purity cultures so that measurements reflect the TEER and 
permeability of endothelial cells and not possible neuronal or non-neuronal 
contaminants [4].  Moreover, we measured how the electrical resistance of 
astrocytes changes over time. Figure 3.3 B demonstrates that this resistance 
can reach as high as 40 (Ω x cm2) (possibly due to the ability of astrocytes to 
form multi-layers), which is very close to the TEER of rat BMEC without any 
cellular or biochemical induction [4,18]. This TEER value for astrocytes further 
emphasizes the importance of statistical methods to analyze co-culture 
results. Furthermore, this change in astrocytes’ resistance properties 
motivated the creation of two co-cultures to further investigate the quality of 
the models when both cell lines reach their peak electrical resistance 
concurrently (model 2) as compared to BAEC reaching their peak but not 
astrocytes (model 1).  
As discussed, the two models are interesting because of the difference 
in the time when BAEC were co-cultured with astrocytes. Astrocytes used in 
both models were derived from the same culture batch, while BAEC used in 
model 2 was one passage older than the one in model 1. We did not expect 
that BAEC in the two models would behave differently as a result of the 
difference in passage number, but TEER data (Figure 3.4) indicate that the 
BAEC used in model 2 had a slightly higher TEER.  
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 Permeability data in both models, and TEER data in model 2 revealed 
no significant difference between the resistance of co-cultures and the BAEC 
alone, but TEER data in model 1 (Figure 3.4 A) illustrated that the resistance 
of co-cultures are significantly less than BAEC alone. We speculated that it is 
possible that if BAEC are seeded within a few hours of astrocytes’ seeding, 
some soluble factors released by astrocytes may negatively affect BAEC, or 
that astrocytic proliferation may deplete some nutrients needed by BAEC from 
the system. 
Although this study revealed no significant difference between the 
properties of BMEC alone and in contact co-culture, care must be used before 
making general conclusions about whether physical contact is necessary in 
these models. Properties of the transwell membrane, such as thickness, pore 
size, and pore density play an important role in determining whether sufficient 
physical contact, and therefore induction, occurs [7,24]. The pore diameter of 
the membranes in this study was 400 nm, and the observation regarding the 
lack of BMEC induction in contact co-culture indicate that this pore size is not 
large enough to promote extension of astrocyte foot processes, and may even 
block the passage of soluble factors. This observation is consistent with a 
previous report by Demeuse et al. [7] that indicated astrocyte foot processes 
did not cross membranes through pores of 450 nm, and therefore did not 
induce brain EC.  
The immunocytochemical characterizations in this study lead to several 
interesting observations. First, immunostaining against occludin in BAEC 
revealed that this junctional protein is either not expressed, or expressed at 
very low levels. Hirase [25] also showed no or minimal expression of occludin 
in primary aortic EC measured by immunostaining and immunoblotting 
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 compared to brain EC. It is less likely that our observation is due to de-
differentiation of BAEC due to passaging because the positive staining for 
uptake of the Ac-LDL is consistent with BAEC that have not lost their 
characteristic properties. Second, the change in morphology of the occludin 
immunostaining in BMEC co-cultures provides further evidence on the 
inducing effects of astrocytes on BMEC. This morphological change may 
correlate with increases at the gene expression level, increases at the protein 
level, or structural changes in occludin such as phosphorylation. Perriere [15] 
indicated that BMEC co-cultured with astrocytes have higher occludin mRNA 
levels compared to BMEC alone. However, future characterizations at the 
protein level are needed to correlate this increased mRNA level with relevant 
protein levels. 
 
3.7 Conclusion 
This study evaluated the induction effects of astrocytes on BAEC, with an 
emphasis on the resistance properties of astrocytes. The linear contrast 
statistical analysis revealed that previously reported decrease in permeability 
of BAEC contact co-cultures, is likely due to the addition of astrocytes’ 
resistance in series and not due to induction. Including BMEC as a control, it 
was also demonstrated that the EC tissue of origin plays a critical role with 
respect to induction by astrocytes compared to the species of origin of the two 
cells (i.e. heterologous models). The lack of occludin expression in BAEC 
provided further evidence that aortic EC are too leaky to be useful for 
constructing in vitro BBB models.  
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 CHAPTER 4 
 
SYNTHESIS AND CHARACTERIZATION OF HIGH-THROUGHPUT 
NANOFABRICATED POLY(HYDROXY STYRENE) MEMBRANES FOR IN 
VITRO MODELS OF BARRIER TISSUE  
 
4.1 Preface 
This chapter is adapted from: Shayan, G., Felix, N., Chatzichristidi, M., Shuler, 
M. L., Ober, C. K., Lee, K. H., 2010. Synthesis and characterization of high-
throughput nanofabricated poly(hydroxy styrene) membranes for in vitro 
models of barrier tissue. Biomaterials, in preparation. It reports on the 
synthesis, nanofabrication, and characterization of high throughput 3 µm thick 
membranes based on poly(hydroxy styrene). These membranes can be used 
as an alternative to current commercially available permeable supports for 
transport studies across in vitro models of barrier tissue. 
 
4.2 Abstract 
Commercially available permeable supports with microporous membranes 
have led to significant improvements in the culture of polarized cells because 
they permit them to feed basolaterally and thus carry out metabolism in a more 
in vivo  like setting. The porous nature of these membranes enable 
permeability measurements of drugs or biomolecules across the cellular 
barrier. However, current porous membranes have a high flow resistance due 
to great thickness (20-40 µm), low porosity, and a wide pore size distribution 
with tortuous diffusion paths which make them low-throughput for permeability 
studies. Here we describe an alternate platform that is more flexible, allows for 
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 more control over physical parameters of the membranes, and is high-
throughput. This study reports on the synthesis and nanofabrication of a 3 µm 
thick, transparent membrane based on poly(hydroxy styrene). The membranes 
are nanofabricated using electron beam lithography and deep ion plasma 
etching to achieve an organized array of straight pores from 50 nm to 800 nm 
in diameter, with at least 23 times less flow resistance. It also shows for the 
first time the potential utility of poly(hydroxy styrene) as a cell culture substrate 
with lack of cytotoxicity, and with suitability for nanofabrication processes due 
to temperature stability.  
 
4.3 Introduction 
The development of culture vessels and cell attachment substrates has been 
driven by the need to produce an environment that resembles the in vivo state 
as closely as possible to enable the growth of specialized cell types. In the 
case of polarized cells, such as epithelial cells and endothelial cells involved in 
barrier tissues, commercially available permeable supports with microporous 
membranes have become the standard tool for cell culture. This technology 
has led to significant improvements in the culture of polarized cells because it 
permits basolateral feeding of cells which facilitates metabolism in a more in 
vivo like setting [1,2]. As an example, it is well established that epithelial cells 
such as MDCK and Caco-2 cells appear squamous and display poor cell 
polarity when grown on solid plastic. However, when these cells are grown on 
permeable supports their morphology dramatically alters to become cuboidal 
and columnar respectively and both display good cell polarity [3]. Moreover, 
cellular functions including transport, adsorption, and secretion can also be 
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 studied because the permeable supports provide convenient and independent 
access to apical and basolateral plasma membrane domains [3,4]. 
Microporous membranes in commercially available permeable supports 
are either made of polyester (partially transparent) or polycarbonate 
(translucent). They are 20-40 µm thick depending on the manufacturer, and 
their pore diameter is either 0.4 µm, 1.0 µm, or 3.0 µm with their nominal pore 
density being 4×106 (polyester) and 1×108 (polycarbonate) pores/cm2. Even 
though polycarbonate membranes possess higher porosity, they are not 
commonly used in cell culture applications due to the difficulty in performing 
microscopy on them. The process of fabrication of these membranes results in 
a random distribution in the size and placement of pores, and more importantly 
the resulting diffusion path is tortuous causing entrapment of biomolecules [5-
12]. Thus, a key drawback of current commercial permeable supports is their 
high flow resistance due to a wide pore size distribution with tortuous paths, 
the low total porosity, and the relatively thick membrane which makes them 
low-throughput for permeability studies [8-12]. 
Here we describe an alternate platform that is more flexible, versatile in 
its physical characteristics, and most importantly high-throughput. A 3 µm 
thick, transparent polymeric membrane based on poly(hydroxy styrene) 
(PHOST) was synthesized. The membranes were then nanofabricated using a 
combination of electron beam lithography with deep ion plasma etching to 
achieve an organized array of straight pores with a narrow size distribution (50 
nm to 800 nm in diameter). The porosity of the membrane is 8×106 pores/cm2, 
which is two times more than commercial membranes. These membranes 
have at least 23 times less flow resistance compared to their commercial 
counterparts, making them ideal for high-throughput permeability studies. 
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 Moreover, we report on preliminary cell culture studies, showing the 
successful attachment and growth of several cell lines commonly used in in 
vitro models of the blood-brain barrier and the intestinal barrier, with focus on 
the viability, rates of metabolism, and differentiation of the cells on the 
nanofabricated membranes.  
 
4.4 Materials and Methods 
4.4.1 Chemicals and Supplies 
Solvents and reagents for the polymer synthesis were obtained from Sigma 
(St. Louis, MO, USA) and used without further purification unless otherwise 
stated. Twelve well Transwell® permeable support (polyester; pore size, 0.4 
μm; pore density, 4x106 pores/cm2) was purchased from Corning (Lowell, MA, 
USA). Poly-D-lysine and collagen type I were purchased from Fisher Scientific 
(Pittsburg, PA, USA). Human fibronectin was purchased from Millipore 
(Billerica, MA, USA). EGM® MV and trypsin-EDTA were purchased from Lonza 
(Basel, Switzerland). Alamar Blue, fetal bovine serum (FBS), and Dulbecco’s 
Modified Eagle Medium (DMEM, with L-glutamin, sodium pyruvate, and low 
glucose), polyclonal rabbit anti-glial fibrillary acidic protein (GFAP) antibody 
(18-0063), rabbit anti-occludin antibody (71-1500), Alexa Fluor® 488 goat anti-
rabbit IgG antibody (A11008), and 4’,6-diamidino-2-phenylindole (DAPI) 
dihydrochloride nuclear stain were also purchased from Invitrogen (Carlsbad, 
CA, USA). Dulbecco’s phosphate buffered saline (DPBS, without CaCl2 and 
MgCl2), HEPES sodium salt, Triton X-100, goat serum, fluorescein sodium 
salt, and gentamicin were purchased from Sigma (St. Louis, MO, USA). 
Paraformaldehyde (16%) was purchased from Electron Microscopy Sciences 
(Ft. Washington, PA, USA). Acetylated low density lipoprotein labeled with 
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 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindo-carbocyanine percholorate (DiI-Ac-
LDL) was purchased from Biomedical Technologies (Stoughton, MA, USA). 
 
4.4.2 Polymer Synthesis 
The reactions used for the preparation of PHOST is based on a modified 
reaction scheme (Figure 4.1) [13-14]. Poly(tert-butoxy styrene) was 
synthesized by free radical polymerization. Briefly, 7.5 mL of 4-tert-butoxy 
styrene (99%) was polymerized in 5 mL of anhydrous toluene at 65ºC with 10 
mg of re-crystallized α,α′-Azoisobutyronitrile (AIBN) as the initiator. All 
glassware was flame dried prior to use and the reaction mixture was purged 
with dry argon for 10 minutes. Polymerization was carried out for 19 hours and 
then terminated in 800 mL of 4ºC methanol. Poly(tert-butoxy styrene) was 
converted to PHOST by a hydrolysis reaction. First, it was dissolved in 20 mL 
of 1,4-dioxane, and then 50 mL of 4M hydrochloric acid in dioxane solution (5-
fold) was added. The mixture was reacted at 80ºC under reflux for 24 hours 
and then precipitated in 800 mL 4ºC water. After neutralization with NaOH 
solution to a pH value of 7 – 7.5, the resulting polymer was filtered and 
lyophilized for 48 hours. 
 
4.4.3 Polymer Characterization 
Gel permeation chromatography (GPC) measurements were performed using 
THF as elution solvent at a flow rate of 1 mL/min in a Waters size exclusion 
chromatograph (SEC). 1H-NMR spectroscopy was performed on 300 MHz 
Mercury 300 NMR instrument using CDCl3 and DMSO-d6 as solvents. FTIR 
measurements were carried out on a Mattson 2020 Galaxy series instrument. 
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Figure 4.1 | Synthesis of PHOST. 
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 Thermal analysis was carried out on a TA instrument DSC (DSCQ1000) and a 
TA instrument TGA (TGAQ500). 
 
4.4.4 Nanofabrication Process 
Figure 4.2 illustrates the fabrication process that was applied to obtain 
spatially controlled nanopores. Briefly, a silicon substrate was cleaned with 
oxygen plasma (standard recipe) in an Oxford Plasmalab 80+ RIE system for 
2 minutes. A solution of poly(acrylic acid) (PAA, 20 wt% in water) was spin-
coated at 2000 rpm for 45 seconds on the substrate followed by baking at 
130ºC for 5 seconds. The layer thickness was 200 nm by profilometry. 
Following the deposition of the PAA layer, a solution of PHOST (15 wt% in 
propylene glycol methyl ether acetate) was spin-coated at 1100 rpm for 30 
seconds followed by baking at 130°C for 1 minute. The layer thickness was 3 
µm by profilometry (at least four scratches were made on the film at different 
locations using a razorblade and the depth of each scratch was measured at 
three different locations).  Low stress thermally grown SiO2 was deposited 
using the IPE 1000 plasma enhanced chemical vapor deposition system at 
115°C for 5 minutes. The layer thickness was 200 – 300 nm.  ZEP-520A 
(positive electron beam resist) was spin-coated at 4000 rpm for 1 minute and 
baked at 115°C for 2 minutes. Leica VB6-HR electron beam lithography 
system (100 kV) was used to write a hexagonal pattern of octagons with the 
current at 1 nA and the exposure dose at 1500 μC/cm2. The pore diameters 
were either 50 nm, 200 nm, 400 nm, 600 nm, or 800 nm with 5 µm center to 
center spacing. The pattern area was a square with an area of 0.25 cm2. The 
exposed samples were developed at 4°C in ZED-N50 for 1 minute, followed 
by methyl isobutyl ketone (MIBK) for 30 seconds, and finally isopropyl alcohol 
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Figure 4.2 | Nanofabrication scheme for obtaining spatially controlled 
nanopores. PHOST was spincoated on a Silicon wafer, followed by the 
deposition of low stress SiO2 layer, and electron beam resist. After electron 
beam exposure, samples were developed at 4°C. A three step etch process 
was used to etch through the SiO2 layer followed by the PHOST. The final 
oxide etch removes the SiO2 layer. Porous membranes are detached from the 
Si wafer by placing them in water and thus dissolving the PAA layer. 
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 (IPA) for 1 minute. The SiO2 mask was etched with a CHF3/O2 recipe in an 
Oxford Plasmalab 80+ RIE system for 6 minutes, and the PHOST was etched 
with an oxygen plasma clean recipe in an Oxford Plasmalab 100 RIE system 
for 2 minutes. Finally, the SiO2 mask was removed with the CHF3/O2 recipe for 
5 minutes. Pore dimensions were characterized using Zeiss Ultra scanning 
electron microscope at 3 kV. 
 
4.4.5 Cell Culture Maintenance 
Astrocytes isolated from 3 days old Wistar rat pups were provided by Dr. W. 
Shain (Wadsworth Center, Albany, NY) following established techniques [15]. 
Cells were maintained in DMEM (low glucose, with L-glutamine and sodium 
pyruvate) supplemented with 5% FBS and gentamicin at the supplier’s 
recommended concentration. Cells were grown on 75 cm2 tissue culture flasks 
at passage 0 and were fed every 3 days by completely replacing the medium.  
Cryo-preserved, single donor, bovine aortic endothelial cells (BAEC) 
were purchased from Lonza (Basel, Switzerland) at passage 1. Cells were 
thawed, maintained, and sub-cultured according to the supplier’s 
recommendations. In summary, cells were maintained in endothelial basal 
medium supplemented with bovine brain extract, heparin, human epidermal 
growth factor, hydrocortisone, gentamicin-amphotericin, and 10% fetal bovine 
serum (EGM® MV). Cells were grown on 25 cm2 tissue culture flasks and used 
at passage 6 for experiments. 
Human colon carcinoma cells (Caco-2) were maintained in DMEM with 
4.5 g/L glucose, 25 mM HEPES buffer, 4 mM L-glutamine, and 10% FBS. 
Cells were used at passage 34. All cultures were maintained in a 37°C 
humidified cell culture incubator with 5% CO2.  
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 4.4.6 Cell Culture on Nanofabricated Membranes 
The PHOST membrane was detached from the silicon substrate after the 
fabrication process by placing it in water. This step dissolved the PAA layer 
and ensured detachment of the membrane from the substrate. An in-house 
support device was designed and made from polycarbonate (Figure 4.3). The 
membrane was chemically attached to the device using methylene chloride. 
After membrane attachment, the device was placed in a 12-well culture dish 
and incubated in an antibiotic solution (100 U/mL penicillin, 100 µg/mL 
streptomycin, and 0.25 µg/mL amphotericin) for 4 hours in culture incubator for 
sterilization. The membrane was washed with DPBS prior to cell culture. 
For astrocyte attachment, both the membrane and a control 
commercially available permeable support were treated with 5 μg/cm2 of poly-
D-lysine in DMEM without serum for 4 hours in the culture incubator. Before 
use, poly-D-lysine was aspirated and the surface was rinsed once with DPBS. 
Astrocytes (passage 1) were seeded at 50,000 cells/cm2 on both surfaces. For 
BAEC, the membrane and the control surface were treated with 10 μg/cm2 of 
human plasma fibronectin in DMEM without serum for 20 minutes in the 
culture incubator. Before use, fibronectin was aspirated and the surface was 
rinsed once with DPBS. BAEC (passage 6) were seeded at 20,000 cells/cm2 
on both surfaces. For Caco-2 attachment, the membrane and the control 
surface were treated with 8 μg/cm2 of collagen type I in water for 20 minutes in 
the culture incubator. Before use, collagen was aspirated and the surface was 
rinsed once with DPBS. Caco-2 (passage 34) were seeded at 100,000 
cells/cm2 on both surfaces. 
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Figure 4.3 | Cell culture support device. After detachment of fabricated 
membranes from the Silicon wafer, they are chemically attached to the top 
cylindrical segment of the device using methylene chloride. The top segment 
will then sit firmly inside the bottom segment with the membrane dividing the 
chambers. The device fits inside a 12-well culture dish. The inner diameter 
(arrow) is 1.12 cm. 
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 Cells were observed with an Olympus inverted phase contrast microscope and 
pictures were captured with a Retiga 1300 CCD camera 1 day and 4 days 
after culture establishment. 
 
4.4.7 Immunocytochemistry 
DiI-Ac-LDL was diluted to 10 μg/mL in EGM® MV and added to BAEC. The 
cells were then incubated in a 37°C humidified cell culture incubator with 5% 
CO2 for 4 hours. The cells were rinsed three times with DPBS and then fixed in 
4% (w/v) paraformaldehyde at room temperature for 20 minutes.  
 Astrocyte and Caco-2 cultures were rinsed twice with DPBS followed by 
fixation in 4% paraformaldehyde for 20 minutes (all steps performed at room 
temperature unless stated otherwise). Following three 5 minute rinses in 
DPBS, astrocytes were permeabilized with 0.1% Triton X-100 in DPBS for 15 
minutes, and Caco-2 cells were permeabilized with 0.05% Triton X-100 for 5 
minutes on ice. (Caco-2 cells were also pre-permeabilized with 0.2% Triton X-
100 for 2 minutes on ice for occludin staining). After three 5 minute rinses in 
DPBS following permeabilization, astrocytes and Caco-2 cells were blocked in 
10% goat serum in DPBS for 15 minutes. All subsequent steps were 
performed on a shaker. The following concentrations in 10% goat serum were 
used for primary antibodies:  rabbit anti-GFAP 4 µg/mL, and rabbit anti-
occludin 15 µg/mL. Primary antibodies were added to the appropriate 
compartment for 1 hour followed by three 10 minutes rinses in 1% goat serum 
(occludin incubation was done at 4°C). Cells were incubated for 1 hour in 
1:500 dilution of Alexa Fluor® 488 goat anti-rabbit IgG antibody followed by 
three 10 minutes rinses in 1% goat serum. DAPI was added in 300 nM for 3 
minutes prior to mounting the membrane on a glass slide with a cover slip in 
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 Vectashield mounting medium. Samples were observed in a Leica SP2 
scanning confocal microscope (Leica Microsystems Inc., Bannockburn, IL, 
USA). 
 Control samples were treated exactly as stated above, except that the 
primary antibodies were replaced with a rabbit IgG fraction negative control. A 
secondary antibody-only control was also included. 
 
4.4.8 Cell Metabolism and Viability Assays 
Alamar Blue (AB) assay, a fluorometric indicator of cell metabolic activity, was 
used to determine cell metabolic rate [16-17]. Prior to the experiment and 
according to the manufacturer’s protocol, the seeding density and incubation 
period consistent with linear reduction of AB was determined by seeding cells 
at various densities and monitoring AB reduction over 72 hours. This initial 
study indicated that for the seeding densities reported for all three cell lines in 
the former section, the maximum incubation time in which the cells turn AB 
from the oxidized form (blue) to the fully reduced form (red) is 24 hours, with 
the signal from the first 6 hours being linear. Thus, twenty four hours post 
seeding, all cultures were fed with a 10% (v/v) solution of AB in culture 
medium and allowed to incubate for 6 hours in the incubator. The fluorescence 
was measured at room temperature every hour in a fluorescent plate reader 
(Molecular Devices SpectraMax Gemini EM) using an excitation and emission 
wavelength of 540 nm and 590 nm, respectively. The fluorescence of an 
empty culture dish and the culture medium were also measured as controls. At 
day 4, all cultures were washed with DPBS and cells were trypsinized from the 
surface. Cell viability was determined with a hemocytometer using 50% 
Trypan Blue.  
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 Three independent experiments were performed with n=4 in each 
experiment. The statistical analysis was carried out using JMP® 7.0 (SAS 
Institute Inc., Cary, NC, USA). Statistical significance was determined using 
one-way analysis of variance (ANOVA) with the global risk fixed at p < 0.05. 
All results are mean ± standard deviation (SD). 
 
4.4.9 Flux Measurements 
The top and bottom compartments of the commercial and nanofabricated 
membranes were pre-equilibrated with transport buffer (10 mM HEPES). A 
solution of sodium fluorescein (376 Da, water soluble) in transport buffer was 
then added to the upper compartments to yield a final concentration of 1 μM. 
Aliquots (100 µL) were removed from the bottom compartment for later 
analysis in a plate reader and the volume replaced with transport buffer every 
15 minutes over 60 minutes. The rate of influx of sodium fluorescein into the 
bottom compartment divided by the total porous area equals the flux [18]. 
 
4.5 Results and Discussion 
Although several attempts have been made to create high flux membranes [8-
12], they are usually targeted towards separation and microfiltration processes 
by creating silicon nitride or silicon oxide nano-films or nano-sieves with limited 
pore sizes (<100 nm) and random pore arrangement. Due to the proposed 
application as well as the extreme fragility of the above membranes, these 
studies come short in showing the absence of cytotoxicity and appropriateness 
for cell culture and tissue engineering. In this study, selection of the 
appropriate polymer involved consideration of two factors. First, the material 
should lack cytotoxicity and require minimum post-fabrication modifications for 
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 cell attachment mainly due to the inherent fragility of a 3 µm thick membrane 
and preference over minimal manipulations. Second, the polymeric membrane 
should have enough thermal resistance to withstand high temperatures 
needed at various nanofabrication steps. This study proposes the potential 
utility of PHOST as a cell culture substrate with suitability for nanofabrication 
processes for the first time. PHOST was chosen over poly(styrene) because 
the presence of the negatively charged hydroxyl group makes it a better 
candidate for cell attachment. More importantly, since the hydroxyl group was 
incorporated into the polymer during the synthesis, the need for post-
fabrication treatment was eliminated.  
 
4.5.1 Synthesis and Characterization of PHOST 
PHOST was prepared in a novel reaction scheme by free radical 
polymerization and subsequent hydrolytic de-protection (Figure 4.1). The 
molecular weight before de-protection was 186,000 g/mol. GPC results 
indicated that the molecular weight distribution (PDI) is 1.7. The high 
molecular weight of PHOST is necessary to ensure proper mechanical stability 
at 3 µm thickness. While Higashimura et al. (1989) proposed a living cationic 
polymerization scheme for PHOST synthesis, our free radical polymerization 
scheme is superior because it is faster, does not require in-lab preparation of 
reactants, is capable of creating high molecular weight PHOST, and involves 
safer chemicals. 
The chemical composition of both polymers was determined by 1H-
NMR spectroscopy (Figure 4.4). A chemical shift of 1.2 ppm corresponds to 
the tert-butyl group of poly(tert-butoxy styrene) in CDCl3. The spectrum of 
PHOST in DMSO-d6 shows a peak at 8.9 ppm, which corresponds to the  
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Figure 4.4 | 1H-NMR spectrum of poly(tert-butoxy styrene) in CDCl3 (A) 
and PHOST in DMSO-d6 (B). 
70 
 hydroxyl group after the de-protection reaction. The polymer backbone protons 
appear in the chemical shift region of 1-2 ppm with the signal due to the tert-
butyl group being disappeared. The FTIR spectrum of PHOST shows a peak 
at 3380 cm-1, which corresponds to the presence of the hydroxyl group after 
de-protection (Figure 4.5). The disappearance of the peak at 1132 cm-1 
indicates complete removal of the tert-butyl ether group during hydrolysis.  
Differential Scanning Calorimetry (DSC) was carried out on both 
polymers (Figure 4.6). The Tg of both poly(tert-butoxy styrene) and PHOST is 
approximately 180°C. Thermogravimetric analysis (Figure 4.7) indicated no 
significant weight loss in PHOST bellow 361°C. The significant weight loss at 
220°C in poly(tert-butoxy styrene) is due to decomposition of the tert-butyl 
group.  
 
4.5.2 Characterization of Nanofabricated Membranes 
Here we describe a nanofabrication scheme that is used for the first time to 
create high resolution porous structures directly on the membranes. Although 
traditional photolithography approaches have long been used in creating 
micro-patterned surfaces, electron beam introduces a higher level of precision 
and resolution. Furthermore, the proposed fabrication scheme provides 
flexibility over the choice of polymer. Also, the process is not limited to thin 
(<500 nm) conducting films (as seen in the semiconductor/mask nano-
patterning using electron beam) due to the presence of an internal mask 
(SiO2). SiO2 is resistant to oxygen etch, and thus can be selectively used as an 
internal mask to transfer the e-beam pattern to PHOST or other underlying 
polymers with thicknesses in the micron or nanometer range. Susceptibility of 
the SiO2  layer to oxide etch however makes its removal easy.  
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Figure 4.5 | FTIR spectra of poly(tert-butoxy styrene) (A) and PHOST (B). 
Arrows correspond to 1132 cm-1 (A) and 3380 cm-1 (B). 
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Figure 4.6 | DSC analysis of poly(tert-butoxy styrene) (A) and PHOST (B). 
T g of both polymers is at 180°C. 
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Figure 4.7 | TGA analysis of poly(tert-butoxy styrene) (A) and PHOST (B). 
The significant weight loss at 220°C in (A) is due to decomposition of the tert-
butyl group. 
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 The PAA layer ensures the complete detachment of fabricated PHOST from 
the Si wafer once the sample is placed in water. Due to extreme hygroscopic 
properties of PAA, it makes a uniform film on the Si wafer only after O2 plasma 
cleaning of the wafer [19]. The thickness of the PAA layer and PHOST were 
200 nm and 3 µm respectively by profilometry. The thickness of PHOST was 
chosen based on its mechanical stability and ease of handling in cell culture.  
ZEP-520A (positive electron beam resist) was specifically chosen over 
more traditional PMMA due its high resolution and more importantly high etch 
resistance [20]. The etch-resistance ensured the complete transfer of pattern 
from ZEP layer all the way down to the SiO2 layer during the CHF3/O2 etch 
process. Cold development temperature was also used to minimize increase 
in the pattern dimensions [21-22]. After the O2 plasma etching of PHOST, 
pores with sloped sidewalls measuring 150-250 nm larger than the target size 
on the patterned side (top side) were typically observed. Figure 4.8 shows 
SEM images of the top-view and cross-section of membranes. The process is 
capable of producing pores with diameters in the range of 50-800 nm. 
After detachment of a fabricated membrane from the Si wafer, it was 
attached to the top cylindrical segment of the in-house support device (Figure 
4.3) using methylene chloride. Even though this may change the thickness 
and chemistry of the membrane at the attachment site (the cross-sectional 
thickness of the ring is 0.2 cm), the chemical attachment is fully controllable 
with respect to creating a leak-proof chamber. Moreover, the inner diameter of 
the support device (and hence the membrane) is 1.12 cm, with the 
nanofabricated portion being a square located at the center of the support 
device (the area of the nanofabricated square is 0.25 cm2). Thus, the  
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Figure 4.8 | Top and cross-sectional views of the porous membrane. Top 
views of 400 nm pores (A) and 600 nm pores (B). Scale bar is 2.5 µm. (C-D) 
shows the cross-section and an angled top view of a 600 nm pore. The larger 
diameter at the top is 828 nm, and the smaller diameter at the bottom is 566 
nm. (E) Top view of a commercial polyester membrane with 400 nm pores. 
The pores are randomly distributed and they are not uniform in size. 
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 nanofabricated region is 0.31 cm away from the attachment site in every 
direction. 
 
4.5.3 Cell Viability, Rate of Metabolism, and Differentiation 
To test the lack of cytotoxicity and cell culture handling ability of very thin 
nanofabricated membranes, astrocytes, BAEC, and Caco-2 cells were 
cultured on PHOST with pores 400 nm in diameter. This pore size was 
selected because the smallest available pore size in commercial permeable 
supports is 400 nm. The three cell lines were chosen to show that the 
membrane is generally applicable to the culture of any cell type, and more 
importantly because these cells are commonly used in constructing in vitro 
models of barrier tissues, blood-brain barrier (BAEC and astrocytes) and the 
intestinal barrier (Caco-2). 
AB was used to determine cell metabolic rate [16-17]. AB is a water-
soluble dye that contains a fluorometric/colorimetric redox indicator that 
changes from the oxidized to the reduced form in response to the chemical 
reduction of the growth medium resulting from cellular metabolism. AB is 
extremely stable and most importantly non-toxic to the cells and thus cultures 
can be monitored continuously over time. The maximum amount of time it 
takes for AB to be completely reduced depends on the cell seeding density. 
Prior to testing the rate of metabolism of cells cultured on the membranes, the 
desired seeding densities were used to determine the incubation period 
consistent with linear reduction of AB over 72 hours. In this experiment, the 
maximum incubation time in which the cells turn AB from the oxidized form to 
the fully reduced form was 24 hours, with the signal from the first 6 hours 
being linear.  
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 Figure 4.9 shows the fluorescence over time for astrocytes, BAEC, and 
Caco-2 cells cultured on the membrane and the control culture dish. According 
to the slopes, the rate of metabolism of astrocytes was 36% lower on the 
membrane compared to the control. For BAEC grown on the membrane the 
rate of metabolism was 19% lower than the control and for the Caco-2 cells 
the rate was statistically the same on both surfaces. The Trypan Blue test 
indicated that cell viability is the same on membranes compared to control 
surfaces for all three cell lines (94%, 96.7%, and 96.9% for astrocytes, BAEC, 
and Caco-2 cells respectively).  
Even though the rate of metabolism of astrocytes and BAEC is lower on 
PHOST, their viability is the same as those cultured on the control surfaces. 
The geometry and consequently the thickness of the liquid film above the cells 
differs in these two constructs (PHOST versus commercial inserts) and the 
different responses maybe due to differences in surface properties or gas 
transfer.  We believe that Caco-2 cells grow as fast on PHOST compared to 
control surfaces because they are transformed (i.e. cancer cell line) and thus 
are robust and properties of the culture substrate may not play a significant 
role on their metabolism. However, in the case of astrocytes which are primary 
cells and thus extremely sensitive, the rate of metabolism is lowest. BAEC are 
also primary cells, but they can be passaged multiple times before they lose 
their properties and thus they are more robust than astrocytes.  
Figure 4.10 shows the phase contrast images of cells 1 day after 
culture establishment on both surfaces (A-F). This shows the ability of the cells 
to adhere to porous PHOST with their morphology being indistinguishable 
from that on the control surface. Phase contrast image of the cells 4 days after 
culture establishment shows the ability of the cells to grow and proliferate on  
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Figure 4.9 | Alamar Blue assay showing cellular rate of metabolism on 
PHOST with 400 nm pores versus the control surface. (A-C) corresponds 
to astrocytes, BAEC, and Caco-2 cells respectively. Three independent 
experiments were performed with n=4 in each experiment. Statistical analysis 
of the data was performed by one-way ANOVA (p < 0.05). All results are mean 
± standard deviation (SD).  
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Figure 4.10 | Cell attachment, growth, and differentiation on PHOST. (A-
C) shows the attachment of astrocytes, BAEC, and Caco-2 cells on PHOST 
with 400 nm pores 1 day after culture establishment. The morphology looks 
indistinguishable from the culture of cells on the commercial permeable 
supports (D-F). (G-I) shows the proliferation of astrocytes, BAEC, and Caco-2 
cells on PHOST with 400 nm pores 4 days after culture establishment. (J-L) 
shows the expression of GFAP in astrocytes, uptake of Ac-LDL in BAEC, and 
the expression of occludin in Caco-2 cells all cultured on PHOST with 400 nm 
pores. Scale bar is 50 µm in all images. 
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 PHOST (Figure 4.10, G-I). Immunocytochemical characterization of BAEC for 
uptake of Ac-LDL (a marker of endothelial cells), astrocytes for the expression 
of glial fibrillary acidic protein (GFAP), and Caco-2 cells for the expression of 
occludin junctional protein shows that the differentiation of these cell types are 
maintained when cultured on porous PHOST (Figure 4.10, J-L). 
 
4.5.4 Flow Resistance Across Nanofabricated Membranes 
As mentioned previously, a key drawback of current commercial permeable 
supports is their high flow resistance due to a wide pore size distribution with 
tortuous paths, the low total porosity, and the relatively thick membrane which 
makes them low-throughput for permeability studies [8-12]. Sodium fluorescein 
was used to assess the flux across the nanofabricated PHOST and 
commercially available permeable supports. The rate of transport of sodium 
fluorescein divided by the porous area is equal to the flux [18]. We evaluated 
the flux over two nanofabricated PHOST membranes both with 400 nm pore 
sizes: one with the same total porosity as a commercial counterpart, and the 
second one with twice the porosity. Figure 4.11 shows the corresponding rates 
of transport across the membranes. These results indicated that the flux over 
PHOST is 23 times higher compared to commercial counterparts due to the 
reduced thickness and the straight pore profiles. When the porosity is doubled, 
flux is 53 times higher compared to commercial membranes. To our 
knowledge, this is the first study that establishes a direct comparison between 
the porosity of commercial membranes versus nanofabricated PHOST and 
reports a minimum of 23 times higher flux. 
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Figure 4.11 | Rate of transport across PHOST with 400 nm pores, its 
commercial counterpart, and PHOST with twice the porosity of the 
commercial membrane. 
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4.6 Conclusion 
In summary, 3 µm thick, transparent, porous polymeric membranes based on 
poly(hydroxy styrene) with defined pore sizes and pore density is 
nanofabricated. The membrane is attached to a support device to facilitate its 
use for cell culture and/or permeability studies. Moreover, the membranes 
have low flow resistance which contributes to their application for high-
throughput permeability and/or separation assays. Cell culture studies show 
the successful attachment, proliferation and differentiation of several cell lines 
that are commonly used in constructing in vitro models of the blood-brain 
barrier, and intestinal barrier. We believe this is the first study that proposes 
the suitability of nonporous PHOST as a high-throughput polymeric membrane 
with lack of cytotoxicity which also has appropriate characteristics for use in 
nanofabrication processes. 
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 CHAPTER 5 
 
MURINE IN VITRO MODEL OF THE BLOOD-BRAIN BARRIER FOR 
EVALUATING DRUG TRANSPORT 
 
5.1 Preface 
This chapter is adapted from: Shayan, G., Choi, Y.S., Shusta, E., Shuler, M. 
L., Lee, K. H., 2010. Murine in vitro model of the blood-brain barrier for 
evaluating drug transport. European Journal of Pharmaceutical Science, in 
preparation. It describes the functional characterization of an in vitro model of 
the blood-brain barrier composed of murine brain microvascular endothelial 
cells co-cultured with primary rat astrocytes in the presence of various 
biochemical inducing agents. These co-cultures are established on 
commercially available inserts made of polyester with 400 nm pores. This 
chapter also presents preliminary characterization data from the same co-
culture model on commercially available inserts made of polycarbonate, and 
an in-house nanofabricated poly(hydroxy styrene) membrane. 
 
5.2 Abstract 
Current in vitro models of the blood-brain barrier (BBB) are composed of brain 
microvascular endothelial cells (BMEC) that are isolated from rat, bovine, or 
porcine. However, these models may not be suitable for studies of BBB in 
brain cancer, neurodegenerative disorders, and inflammatory events involving 
the CNS because these diseases are generally studied in mouse models and 
thus murine in vitro BBB models serve as better surrogates to correlate with 
these studies. Here we describe the functional characterization of a 
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 reproducible in vitro model composed of murine BMEC co-cultured with 
primary rat astrocytes in the presence of various biochemical inducing agents 
on commercially available polyester inserts with 400 nm pores. The co-
cultures presented high TEER and low sodium fluorescein permeability. 
Expression of specific BBB tight junction proteins (occludin, claudin-5, ZO-1) 
and the functionality of transporters (Pgp, GLUT1) were detected by 
immunocytochemistry and western analysis. These results indicated a 2.5 fold 
increase in the expression levels of these proteins in the presence of 
astrocytes versus BMEC alone. In addition, a high correlation coefficient (0.98) 
was obtained between the permeability coefficients of a series of hydrophobic 
and hydrophilic drugs and their corresponding in vivo murine BBB transfer 
coefficients. These results together establish the utility of this murine model for 
future pathological, physiological, and pharmacological characterizations of 
the BBB.  
 
5.3 Introduction 
The blood-brain barrier (BBB) is comprised of a specialized class of 
endothelial cells (EC) that line the cerebral vasculature and is an important 
barrier for protecting the brain from fluctuations in plasma composition [1-2]. 
By restricting non-specific flux of blood-borne molecules, the BBB plays an 
important role in maintaining parenchymal homeostasis, and strictly regulates 
transport of ions, small molecules, proteins, and cells into and out of the brain 
[3]. The specialized capillary endothelium in the brain is endowed by high 
electrical resistance tight junctions joining adjacent EC that force most 
molecular traffic to take a transcellular route across the BBB rather than 
moving paracellularly through the tight junctions. These EC lack fenestrae and 
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 possess very few endocytotic vesicles, thereby limiting the amount of 
transcellular flux [3]. 
 In vitro models of the BBB have been developed to better understand 
the underlying cell biology, to predict drug permeability prior to animal studies, 
and to overcome the inherent difficulty in performing BBB molecular level 
studies in vivo [4]. These in vitro models [5-18] serve as successful surrogates 
to in vivo experiments and provide a critical framework for BBB studies. 
Recent updates in the construction of in vitro models include improved 
techniques to isolate brain microvascular endothelial cells (BMEC) [8,14,18] 
induction of BMEC with astrocytes, pericytes, or biochemical agents [5,9,11-
14,17].  
Structurally, the cell type closest to brain capillary EC is the astrocyte 
and their processes form endfeet that collectively surround cerebral 
microvessels [7,9,10,16,19,20]. As a result, several models have focused on 
recreating the brain microenvironment by incorporating astrocyte co-cultures, 
or astrocyte conditioned-medium to further induce BMEC. Traditionally, many 
models involve a contact or often a non-contact co-culture between EC and 
astrocytes on commercially available microporous filters. Furthermore, rat or 
bovine BMEC co-cultured with rat astrocytes were shown to have higher 
transendothelial electrical resistance (TEER) and lower permeability compared 
to BMEC cultures alone [7,9-11,14,18].  
Despite these advances, the majority of current in vitro models are 
based on BMEC that are isolated from rat or bovine. Use of such models may 
not be suitable for studies of BBB in brain cancer, neurodegenerative 
disorders, and inflammatory events involving the CNS because these diseases 
are generally studied in mouse models and thus in vitro BBB models using 
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 murine BMEC may be a better basis for comparison [21-22]. The purpose of 
this study was a detailed characterization of a mouse BMEC model co-
cultured with rat astrocytes in contact and without contact on commercially 
available polyester inserts with 400 nm pores for the first time. Rat astrocytes 
were chosen in preference to mouse astrocytes due to ease of culture and 
higher yields. The model was characterized by looking at transendothelial 
electrical resistance (TEER), sodium fluorescein permeability, qualitative and 
quantitative expression of tight junction proteins, influx, and efflux transporters. 
Furthermore, in vitro permeability of a group of hydrophilic and hydrophobic 
drugs were evaluated and correlated with in vivo permeability data from 
mouse and a correlation coefficient of 98% was found.  
This study also reports on the preliminary characterization results of the 
same co-culture model on commercially available polycarbonate inserts (400 
nm pores), as well as an in-house nanofabricated poly(hydroxy styrene) 
(PHOST) membrane (400 nm and 800 nm pores) to evaluate the effects of 
membranes’ physical parameters (material, thickness, and pore size) on the 
integrity of the BBB model. 
 
5.4 Materials and Methods 
5.4.1 Chemicals and Supplies 
Poly-D-lysine and L-glutamine were purchased from Fisher Scientific 
(Pittsburg, PA, USA). Human fibronectin was purchased from Millipore 
(Billerica, MA, USA). Twenty four well Transwell® permeable support 
(polyester and polycarbonate; thickness, 10 μm; pore size, 0.4 μm; pore 
density, 4x106 pores/cm2 and 1x108 ,respectively) were purchased from 
Corning (Lowell, MA, USA). Fetal bovine serum (FBS), Dulbecco’s Modified 
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 Eagle Medium (DMEM, with l-glutamin, sodium pyruvate, and low glucose), 
Ham’s F-12 nutrient mixture, TrypLE, and Penicillin-Streptomycin-Amphotercin 
(PSA) were purchased from Invitrogen (Carlsbad, CA, USA). Dulbecco’s 
phosphate buffered saline (DPBS, without CaCl2 and MgCl2), gentamicin, 
HEPES sodium salt, fluorescein sodium salt, Heparin, bovine serum albumin, 
puromycin, hydrocortisone, insulin-transferrin-sodium selenite supplement, 
retinoic acid, caffeine, prazosin, trazodone, propranolol, hydroxyzine, atenolol, 
cimetidine, DMSO, Krebs-Ringer buffer, collagen type IV, Triton X-100, and 
goat serum were purchased from Sigma (St. Louis, MO, USA). 8-CPT-cAMP 
and RO20-1724 were purchased from Biomol (Plymouth Meeting, PA). Percoll 
was purchased from Amersham Biosciences (Piscataway, NJ, USA). Type II 
collagenase and DNase I were purchased from Worthington Biochemical 
Corp. (Lakewood, NJ, USA). Collagenase-dispase and basic fibroblast growth 
factor were purchased from Roche Molecular Biochemicals (Indianapolis, IN, 
USA). Paraformaldehyde (16%) was purchased from Electron Microscopy 
Sciences (Ft. Washington, PA, USA). Acetylated low density lipoprotein 
labeled with 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindo-carbocyanine 
percholorate (DiI-Ac-LDL) and bovine platelet-poor plasma-derived serum 
were purchased from Biomedical Technologies (Stoughton, MA, USA). 
Polyclonal rabbit anti-glial fibrillary acidic protein (GFAP) antibody (18-0063), 
rabbit anti-occludin antibody (71-1500), rabbit anti-claudin5 antibody (34-
1600), rabbit anti-ZO1 antibody (61-7300), Alexa Fluor® 488 goat anti-rabbit 
IgG antibody (A11001), and 4’,6-diamidino-2-phenylindole (DAPI) 
dihydrochloride nuclear stain were also purchased from Invitrogen (Carlsbad, 
CA, USA). Mouse anti-MDR1 (SC-55510) and rabbit anti-Glut1 (SC-7903) 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
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 Vectashield mounting medium was purchased from Vector Laboratories 
(Burlingame, CA, USA). EVOM voltohmmeter (STX2) was purchased from 
World Precision Instruments (Sarasota, FL, USA). Solvents and reagents for 
the polymer synthesis were obtained from Sigma (St. Louis, MO, USA) and 
used without further purification unless otherwise stated. 
 
5.4.2 Polymer Synthesis 
The reactions used for the preparation of PHOST is based on a modified 
reaction scheme [23-24]. Poly(tert-butoxy styrene) was synthesized by free 
radical polymerization. Briefly, 7.5 mL of 4-tert-butoxy styrene (99%) was 
polymerized in 5 mL of anhydrous toluene at 65ºC with 10 mg of recrystallized 
α,α′-Azoisobutyronitrile (AIBN) as the initiator. All glassware was flame dried 
prior to use and the reaction mixture was purged with dry argon for 10 
minutes. Polymerization was carried out for 19 hours and then terminated in 
800 mL of 4ºC methanol. Poly(tert-butoxy styrene) was converted to PHOST 
by a hydrolysis reaction. First, it was dissolved in 20 mL of 1,4-dioxane, and 
then 50 mL of 4M hydrochloric acid in dioxane solution (5-fold) was added. 
The mixture was reacted at 80ºC under reflux for 24 hours and then 
precipitated in 800 mL 4ºC water. After neutralization with NaOH solution to a 
pH value of 7 – 7.5, the resulting polymer was filtered and lyophilized for 48 
hours. 
 
5.4.3 Nanofabrication Process 
Briefly, a silicon substrate was cleaned with oxygen plasma (standard recipe) 
in an Oxford Plasmalab 80+ RIE system for 2 minutes. A solution of 
poly(acrylic acid) (PAA, 20 wt% in water) was spin-coated at 2000 rpm for 45 
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 seconds on the substrate followed by baking at 130ºC for 5 seconds. The 
layer thickness was 200 nm by profilometry. Following the deposition of the 
PAA layer, a solution of PHOST (15 wt% in propylene glycol methyl ether 
acetate) was spin-coated at 1100 rpm for 30 seconds followed by baking at 
130°C for 1 minute. The layer thickness was 3 µm by profilometry (at least four 
scratches were made on the film at different locations using a razorblade and 
the depth of each scratch was measured at three different locations).  Low 
stress thermally grown SiO2 was deposited using the IPE 1000 plasma 
enhanced chemical vapor deposition system at 115°C for 5 minutes. The layer 
thickness was 200 – 300 nm.  ZEP-520A (positive electron beam resist) was 
spin-coated at 4000 rpm for 1 minute and baked at 115°C for 2 minutes. Leica 
VB6-HR electron beam lithography system (100 kV) was used to write a 
hexagonal pattern of octagons with the current at 1 nA and the exposure dose 
at 1500 μC/cm2. The pore diameters were either 400 nm, or 800 nm with 5 µm 
or 10 µm center to center spacing, respectively (corresponding to 4x106 
pores/cm2  and 1x106 pores/cm2, respectively). The pattern area was a square 
with an area of 0.29 cm2. The exposed samples were developed at 4°C in 
ZED-N50 for 1 minute, followed by methyl isobutyl ketone (MIBK) for 30 
seconds, and finally isopropyl alcohol (IPA) for 1 minute. The SiO2 mask was 
etched with a CHF3/O2 recipe in an Oxford Plasmalab 80+ RIE system for 6 
minutes, and the PHOST was etched with an oxygen plasma clean recipe in 
an Oxford Plasmalab 100 RIE system for 2 minutes. Finally, the SiO2 mask 
was removed with the CHF3/O2 recipe for 5 minutes. Pore dimensions were 
characterized using Zeiss Ultra scanning electron microscope at 3 kV. 
The PHOST membrane was detached from the silicon substrate after 
the fabrication process by placing it in water. This step dissolved the PAA 
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 layer and ensured detachment of the membrane from the substrate. An in-
house support device was designed and made from polycarbonate (Figure 
5.1). The membrane was chemically attached to the device using methylene 
chloride. After membrane attachment, the device was placed in a 12-well 
culture dish and incubated in an antibiotic solution (100 U/mL penicillin, 100 
µg/mL streptomycin, and 0.25 µg/mL amphotericin) for 4 hours in culture 
incubator for sterilization. The membrane was washed with DPBS prior to cell 
culture. 
 
5.4.4 Isolation of Rat Astrocytes 
Astrocytes isolated from 3 days old Wistar rat pups were provided by Dr. W. 
Shain (Wadsworth Center, Albany, NY) following established techniques [25]. 
Cells were maintained in DMEM (low glucose, with L-glutamine and sodium 
pyruvate) supplemented with 5% FBS and gentamicin at the supplier’s 
recommended concentration. Cells were grown on 75 cm2 tissue culture flasks 
at passage 0 and were fed every 3 days by completely replacing the medium. 
Cultures were maintained in a 37°C humidified cell culture incubator with 5% 
CO2.  
 
5.4.5 Isolation of Murine Brain Microvascular Endothelial Cells (BMEC) 
Isolation of murine BMEC was based on a modified protocol [5,17]. All animals 
were treated according to protocols evaluated and approved by IACUC at the 
University of Delaware. In summary, 10 adult wild type male mice (C57Bl/6) 
were euthanized under CO2. Forebrains were collected and stored in DMEM 
on ice. The remainder of the isolation took place under aseptic conditions. The  
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Figure 5.1 | Cell culture support device. After detachment of fabricated 
membranes from the Silicon wafer, they are chemically attached to the 
cylindrical segment of the device using methylene chloride. The device fits 
inside a 12-well culture dish. The arrows represent 1.5 cm and 2.5 cm, 
respectively. 
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 brains were cut sagittally into two haves and rolled on Whatman 3MM 
chromatography paper to remove the meninges. The cortices were dissected 
away and much of the white matter was removed. The cortices were smashed 
with forceps and completely triturated and digested with 0.69 mg/mL type II 
collagenase and 37.6 U/mL DNase I in DMEM for 1 hour in 37°C shaker (250 
rpm). The enzyme solution was then diluted in DMEM and centrifuged at 1000 
g  for 8 minutes at room temperature. To remove myelin the pellet was 
resuspended in 20% (w/v) bovine serum albumin in DMEM and centrifuged at 
1000 g for 20 minutes. The pellet was resuspended and further digested with 
0.69 mg/mL collagenase-dispase and 28.3 U/mL DNase I in DMEM for 1 hour 
in 37°C shaker (200 rpm). The micro-vessels were separated on a 33% 
continuous Percoll gradient, collected and plated in a 35mm petri-dish coated 
with collagen type IV and fibronectin. Cultures were maintained in DMEM 
supplemented with 4 µg/mL puromycin, 20% bovine platelet-poor plasma-
derived serum, 1 ng/mL human basic fibroblast growth factor, 1 µg/mL 
heparin, 2 mM L-glutamine, and an antibiotic solution (100 U/mL penicillin, 100 
µg/mL streptomycin, and 0.25 µg/mL amphotericin). Culture medium was 
completely replaced every day, and puromycin was removed from the medium 
on day 3. Cells were subcultured on day 3.5 using 1 mL TrypLE and seeded 
on commercial transwells or nanofabricated PHOST coated with collagen type 
IV and fibronectin at 300,000 cells/cm2.  Cultures were maintained in Ham’s F-
12:DMEM  (1:1) supplemented with 2 mM L-glutamine, 550 nM 
hydrocortisone, 312.4 µM cAMP, 17.5 µM phosphodiesterase inhibitor, 1 µM 
retinoic acid, 5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL sodium selenite, 
and an antibiotic solution (100 U/mL penicillin, 100 µg/mL streptomycin, and   
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 0.25 µg/mL amphotericin). Cultures were maintained in a 37°C humidified cell 
culture incubator with 5% CO2.  
 
5.4.6 Co-Culture Setup 
Co-cultures were set up on four different membranes: commercial polyester 
membrane with 400 nm pores, 4x106 pores/cm2, commercial polycarbonate 
membrane with 400 nm pores and 1x108 pores/cm2, 3 µm thick PHOST with 
400 nm pores and 4x106 pores/cm2, and PHOST with 800 nm pores and 1x106 
pores/cm2. The pore densities on PHOST were chosen so that their total 
porosity (regardless of the pore size) will be the same as commercial polyester 
membranes.  
Two different co-cultures were set up. In the contact co-cultures, 
astrocytes and BMEC were seeded on the opposite sides of the membranes, 
while in the non-contact co-cultures astrocytes were seeded on the multi-well 
dish and BMEC on the membrane. For better astrocyte attachment the 
backside of the membrane, or the bottom of the multi-well dish, were treated 
with 5 μg/cm2 of poly-D-lysine in DMEM without serum for one hour in culture 
incubator. Before use, poly-D-lysine was aspirated and the surface was rinsed 
once with DPBS. Astrocytes (passage 1) were seeded at 80,000 cells/cm2 
either on the bottom of the dish (non-contact co-culture) or on the backside of 
the membrane (contact co-culture). After 20 minutes, all transwells were 
flipped over inside a 24-well culture dish containing DMEM supplemented with 
5% FBS in the bottom compartment and were fed every day for three days 
before the addition of BMEC. On day three, the astrocyte medium was 
changed to BMEC medium (Ham’s F-12:DMEM  (1:1) supplemented with 2 
mM L-glutamine, 550 nM hydrocortisone, 312.4 µM cAMP, 17.5 µM 
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 phosphodiesterase inhibitor, 1 µM retinoic acid, 5 µg/mL insulin, 5 µg/mL 
transferrin, 5 ng/mL sodium selenite, and an antibiotic solution) and BMEC 
were added to the transwells as described in the previous section. 
Controls included empty transwell with the top-side of the membrane 
coated with collagen type IV and fibronectin and bottom-side coated with poly-
D-lysine, murine BMEC and astrocyte only transwells. Culture medium in both 
compartments was replaced completely every 3 days. All measurements were 
performed 6 days after BMEC seeding. 
 
5.4.7 Transendothelial Electrical Resistance Measurements  
Transendothelial electrical resistance (TEER) was measured using an EVOM 
voltohmmeter (STX2) 6 days after establishment of co-culture. Final resistance 
(Ω x cm2) was calculated after subtracting the resistance of an empty filter. 
Three TEER measurements were made per transwell and the arithmetic mean 
calculated. Unless specified, TEER measurements of three transwells for each 
culture condition were used to compute the mean and standard deviations 
reported.  
 
5.4.8 Sodium Fluorescein Permeability Measurements 
Prior to permeability studies, culture media from the top and bottom 
compartments was replaced with pre-equilibrated transport buffer (10 mM 
HEPES, 0.1% w/v bovine serum albumin, 4.5% w/v glucose). A solution of 
sodium fluorescein (376 Da) in transport buffer was then added to the upper 
compartment of the transwell to yield a final concentration of 1 μM. Aliquots 
(100 µL) were removed from the bottom compartment and the volume 
replaced with pre-equilibrated transport buffer every 15 minutes over 60 
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 minutes. Based on the rate of influx of sodium fluorescein into the bottom 
compartment, permeability coefficients were calculated [8]. 
 
5.4.9 Uptake of DiI-Ac-LDL 
DiI-Ac-LDL was diluted to 10 μg/mL in BMEC medium and added to the upper 
compartment containing BMEC prior to other immunofluorescent studies. The 
cells were then incubated in a 37°C humidified cell culture incubator with 5% 
CO2 for 4 hours. The cells were rinsed three times with DPBS and then fixed in 
4% (w/v) paraformaldehyde at room temperature for 20 minutes.  
 
5.4.10 Immunocytochemistry 
All cultures were rinsed twice with DPBS followed by fixation in 4% 
paraformaldehyde for 20 minutes (all steps performed at room temperature 
unless stated otherwise). Following three 5 minute rinses in DPBS, astrocytes 
were permeabilized with 0.1% Triton X-100 in DPBS for 15 minutes, and 
BMEC were permeabilized with 0.05% Triton X-100 for 5 minutes on ice 
(BMEC were also pre-permeabilized with 0.2% Triton X-100 for 2 minutes on 
ice if staining for occludin). After three 5 minute rinses in DPBS following 
permeabilization, astrocytes and EC were blocked in 10% goat serum in 
DPBS for 15 and 7 minutes, respectively. All subsequent steps were 
performed on a shaker. The following concentrations in 10% goat serum were 
used for primary antibodies:  rabbit anti-GFAP 4 µg/mL, rabbit anti-occludin 15 
µg/mL, rabbit anti-ZO1 and rabbit anti-claudin5 5 µg/mL. Primary antibodies 
were added to the appropriate compartment for 1 hour followed by three 10 
minutes rinses in 1% goat serum. Cells were incubated for 1 hour in 1:500 
dilution of Alexa Fluor® 488 goat anti-rabbit IgG antibody followed by three 10 
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 minutes rinses in 1% goat serum. DAPI was added in 300 nM for 3 minutes 
prior to mounting the membrane on a glass slide with a cover slip in 
Vectashield mounting medium. Samples were observed in a Leica SP2 
scanning confocal microscope (Leica Microsystems Inc., Bannockburn, IL, 
USA). Control samples were treated exactly as stated above, except that the 
primary antibodies were replaced with a rabbit IgG fraction negative control. A 
secondary antibody-only control was also included. 
 To assess whether astrocytes clog the 400 nm pores on polyester 
membranes, samples were fixed in 4% paraformaldahyde at 4°C for 
approximately 2 weeks. The membranes were labeled red using FM4-64 
hydrophobic dye and the cells were labeled green using Syto13 nucleotide 
dye.  The images were taken on a Zeiss AxioObserver Z1 inverted microscope 
configured as an LSM 5DUO confocal, using a 100x α Plan Apochromat 
(NA=1.45).  The FM4-64 was excited at 560 nm laser (20.9% power) and 
emitted light was collected using a long pass filter (575).  Syto13 was excited 
with a 488 nm laser (1.9% power) and emitted light was collected using a band 
pass filter at (505 – 550 nm).  Reflected light off the surface of the membranes 
was visualized with a 633nm laser. Channels were collected in fast line 
switching mode, and 175 slices were acquired at 0.12 um intervals.   
 
5.4.11 Western Blotting 
Six days after establishing the co-cultures, Laemmli sample buffer was used to 
collect cell lysates. 20 µL of protein lysate was resolved by SDS-PAGE (12% 
w/v) using Tris-HCl and immunoblotted. All subsequent steps were done at 
room temperature. Membranes were blocked in 3% non-fat dry milk for one 
hour and then probed with rabbit anti-occludin (1 µg/mL), rabbit anti-claudin5 
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 (1 µg/mL), rabbit anti-GLUT1 (4 µg/mL), or mouse anti-MDR1 (Pgp) (4 µg/mL). 
Following washing steps, the membranes were incubated with alkaline 
phosphatase conjugated goat anti-mouse IgG or mouse anti-rabbit IgG 
(1:30,000 dilution). Bound antibodies were detected using enhanced chemi-
fluorescence (ECF) substrate following the manufacturer’s instructions and 
imaged using a FLA-3000 Fujifilm scanner. 
 
5.4.12 In Vitro Drug Permeability Study 
To measure the flux of hydrophobic and hydrophilic drugs selected for the 
study (Table 5.1) across the co-cultures, inserts were transferred to clean 24-
well plates containing 0.6 mL Ringer-Hepes buffer in the lower compartment.  
All test drugs were dissolved in DMSO to yield a 1 mM solution. The upper 
compartment was then filled with 0.1 mL of 1 µM drug solution in Ringer-
Hepes buffer. The inserts were transferred at 20, 40, and 60 minutes to a new 
well containing fresh buffer. The concentration of the drugs in the upper and 
lower compartments were measured by liquid chromatography-mass 
spectrometry (LC-MS) (described below) and based on the rate of influx of 
each drug into the bottom compartment, permeability coefficients were 
calculated and correlated with in vivo permeability of the drugs in mice [13]. 
 
5.4.13 LC-MS Analysis 
To remove insoluble materials and large molecules, samples and standards 
were filtered through 3 kDa molecular weight cut-off filter (Millipore Micron YM-
3 ) at 10,000 rpm for 25 minutes. 50 μL of each filtrate was separated by an 
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Table 5.1 | List of drugs selected for transport studies. Pe Values are 
calculated using a tissue distribution model in mice reported in Nakagawa et. 
al [13]. Permeability values are (10-6 cm/s). 
 
Name MW CNS Transport Pe 
Atenolol 226 - Passive Hydrophilic 2.49 
Caffeine 212 + Passive lipophilic 496.67 
Cimetidine 252 - Efflux: Pgp, BCRP 2.99 
Hydroxyzine 448 + Passive lipophilic 1174.04 
Prazosin 420 - Efflux: Pgp, BCRP 22.91 
Propranolol 296 + Passive lipophilic 1987.16 
Trazodone 408 + Passive lipophilic 333.61 
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 Agilent 1100 series LC system with two mobile phases: a 0.1% formic acid in 
water, and a 0.1% formic acid in acetonitrile at a flow rate of 400 μL/min. In 
this system, a two-way divert valve (10 ports, Valco Instruments Co. Inc., 
Houston, TX), an adjustable splitter (Analytical Scientific Instruments, El 
Sobrante, CA), a micro-tee connector (Upchurch Scientific, Oak Harbor, WA), 
and restrictor capillaries (25um ID, Upchurch Scientific) were used for the 
online desalting of samples and standards. First, with the valve position at 
“load/wash”, samples and standards were introduced on a guard column (C18, 
4 x 3.00 mm, Phenomenex, Torrance, CA) by the autosampler and their salts 
were washed away by 100% formic acid in water for 6 minutes. Then, the 
valve position was changed to “injection” for the delivery of analytes retained 
at the guard column to an analytical column (Luna 3μ, C18, 100 x 2.00 mm, 
Phenomenex) by a gradient mobile phase programming (0% to 80% formic 
acid in acetonitrile for 30 minutes). At the “load/wash” valve position, the actual 
flow rate at the guard column was about 250 μL/min and at the “injection” 
position, the actual flow rate at the analytical column was about 200 μL/min. 
Analytes eluted from the analytical column were directly introduced into an 
Applied Biosystems QTRAP mass spectrometer through its Turbospray source 
(curtain gas of 20.0 psi, high collision gas, ion spray voltage of 5200 V, 
temperature of 450 °C, ion source gas1 of 20 psi, and ion source gas2 of 40 
psi) and analyzed by using full mass scan (mass range between 100 and 1400 
m/z, scan rate of 4000 amu/s, and dynamic fill time) in the positive ion mode. 
 
5.4.14 Statistical Analysis  
The statistical analysis was carried out using JMP® 7.0 (SAS Institute Inc., 
Cary, NC, USA). Statistical evaluation of the resistance and permeability data 
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 was performed using a least square linear regression model. All results are 
mean ± standard deviation (SD). 
 The influence of astrocytes on the resistance and permeability of BMEC 
in contact and non-contact co-cultures was evaluated using one-way analysis 
of variance (ANOVA) with linear contrast. The global risk was fixed at p < 0.05 
for all tests. 
 
5.5 Results 
5.5.1 Immunocytochemical Characterization of Murine BMEC and Astrcoytes 
BMEC cultured alone or in the presence of astrocytes grew in non-overlapping 
continuous monolayers and displayed a tightly apposed characteristic spindle 
shaped morphology (Figure 5.2 A). BMEC cultures in co-culture with 
astrocytes in contact and without contact retained their phenotype as judged 
by the uptake of DiI-Ac-LDL (Figure 5.2 B). Astrocytes cultured on the bottom 
side of the transwell as well as in the multi-well dish, attached and proliferated 
well and retained their phenotype as judged by GFAP antibody staining 
(Figure 5.2 C).  
 
5.5.2 Paracellular Permeability of the Co-Cultures 
In both co-cultures and controls, paracellular permeability of the endothelial 
layer was monitored by measuring the TEER and the rate of influx of sodium 
fluorescein from the top compartment of the transwell to the bottom. 
Representative influx rates over the transwell membrane area correspond to 
the permeability coefficient for each configuration.  
 In the TEER study, regardless of the type of membrane used, the 
statistical analysis of the data revealed a significant increase in resistance of  
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Figure 5.2 | Immunocytochemical characterization of BMEC and 
Astrocytes. (A) Phase contrast image of BMEC in transwell. (B) 
Immunofluorescent confocal image of BMEC probed for uptake of DiI-Ac-LDL. 
(C) Immunofluorescent confocal image of astrocytes probed for glial fibrillary 
acidic protein (GFAP). Scale bars represent 50 μm. 
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 BMEC in the non-contact co-cultures (Figure 5.3). The resistance of BMEC 
alone controls and the contact co-cultures were statistically similar.   
The paracellular permeability of BMEC as measured by the influx rate 
of water soluble small marker sodium fluorescein also revealed similar results 
to TEER (Table 5.2). The permeability was statistically lowest in non-contact 
co-cultures compared to BMEC alone, or the sum of BMEC and astrocytes in 
contact co-cultures.  
Permeability and TEER results on PHOST membranes with different 
pore sizes were statistically similar. However, the overall resistance of BMEC 
on PHOST and polycarbonate was lower than on commercial polyester 
membranes with similar pore size and total porosity. 
 
5.5.3 Expression of Transporters and Tight Junction Proteins 
BMEC cultured alone and in contact, or non-contact, co-cultures on polyester 
membranes were examined by immunocytochemistry for the expression and 
morphological distribution of intercellular tight junction proteins claudin-5, 
occludin, and ZO-1 (Figure 5.4). While all three proteins are clearly expressed 
in the different culture conditions, the morphological distribution is smooth in 
the BMEC alone cultures and turns to a more “zig zag” like configuration in co-
cultures. This zig zag configuration is more clear in the morphology of claudin-
5 and occludin in the non-contact co-cultures.  
 To further assess possible changes in the expression level of claudin-5 
and occludin in the different culture conditions, western analysis was 
performed (Figure 5.5). The results indicated that claudin-5 and occludin 
expression increases 2.5 fold in the non-contact co-cultures. Western analysis 
was also performed to confirm the expression of P-glycoprotein (Pgp) and 
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Figure 5.3 | TEER of BMEC and astrocytes on polyester, 
polycarbonate, and PHOST with 400 nm or 800 nm pores. The TEER 
of BMEC and contact co-cultures (BMEC/Astro) are statistically similar, 
while the TEER of the non-contact co-cultures (BMEC-Astro) are 
statistically higher. BMEC have lower resistance on polycarbonate and 
PHOST. Results are the means ± SD of 2-3 transwells. Statistical 
analysis of the data was performed by one-way ANOVA (p < 0.05) along 
with linear contrast analysis for contact co-cultures. Star represents 
statistical significance. Star represents statistical significance. 
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Table 5.2 | Sodium fluorescein permeability on polyester, polycarbonate, 
and PHOST with 400 nm or 800 nm pores. Permeability values are (10-6 
cm/s). Star represents statistical significance. 
 
Culture Type Polyester Polycarbonate PHOST 400 nm PHOST 800 
Astrocyte 25 ± 0.2* 31 ± 0.7* 27 ± 0.4* 23 ± 0.5* 
BMEC 6.5 ± 0.8 7.4 ± 0.1 19.4 ± 0.2 17 ± 0.2 
Contact 6.1 ± 0.5 7.8 ± 0.4 18.7 ± 0.3 15.8 ± 0.1 
Non-contact 3.5 ± 0.1*  6.0 ± 0.1* 13.9 ± 0.3*  11.4 ± 0.5*  
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Figure 5.4 | Immunocytochemistry of tight junctions on polyester. 
Confocal images of BMEC, contact (BMEC/Astro), and non-contact (BMEC-
Astro) co-cultures stained for the expression of claudin-5, occludin and ZO-1. 
The “zig-zag” morphology is more evident in the non-contact co-cultures. 
Scale bars represent 20 μm. 
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Figure 5.5 | Expression levels of tight junction proteins and transporters 
on polyester. Western blot results show a 2.5 fold increase in the expression 
levels of claudin-5, occludin, and P-glycoprotein in the non-contact co-cultures. 
The results also show the expression of glucose transporter-1. 
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 glucose transporter-1 (GLUT1), and it indicated an increase in the expression 
of both proteins in the non-contact co-cultures. 
 
5.5.4 Drug Permeability and Correlation with In Vivo Data 
The non-contact co-cultures of BMEC and astrocytes on polyester membranes 
were further characterized by measuring the permeability of compounds with 
known permeability properties in vivo (Table 5.1). These compounds include 
hydrophobic and hydrophilic drugs. All molecules that enter the BBB by lipid-
mediated free diffusion (caffeine, hydroxyzine, propranolol, trazodone) 
displayed a high permeability when measured on the model (Figure 5.6). In 
contrast the permeability of small hydrophilic compounds (atenolol, cimetidine, 
prazosin) was small. When the data obtained from the in vitro model was 
compared with the in vivo values, a correlation coefficient of 0.98 was found. 
 
5.6 Discussion 
This study has primarily focused on the development of facile and reproducible 
methods for cultivating mouse BMEC and further co-culturing them with 
primary rat astrocytes to make an in vitro BBB model with more authentic 
permeability properties. It further included preliminary experiments to assess 
resistance properties of BMEC on various materials, and whether reduced 
membrane thickness or increased pore size and porosity facilitates the 
induction by astrocytes. We believe this is the first study that reports on a 
complete characterization of an in vitro BBB model based on a co-culture of 
mouse BMEC and rat astrocytes by study of TEER, sodium fluorescein 
permeability, qualitative and quantitative expression of tight junction proteins, 
Pgp, and GLUT-1. Further, we correlated permeability of multiple hydrophobic 
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Figure 5.6 | Drug permeability correlation studies. Correlation between 
permeability coefficients of drugs tested in the in vitro model (non-contact co-
cultures) and the apparent permeability coefficients measured in mice (Table 
5.1). The R2 value represents the fitness of the straight line, while the actual 
correlation coefficient is 0.98. Results were replicated in three independent 
experiments. 
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 and hydrophilic drugs in the in vitro model with in vivo data from mouse to 
establish utility of the model for drug development testing by obtaining a 98% 
correlation coefficient on polyester commercial membranes. Previously 
characterized in vitro models based on BMEC isolated from rat or bovine in 
co-culture with astrocytes, or in triple co-culture with astrocytes and pericytes 
have reported drug permeability correlation coefficients ranging from 89% to 
94% [4,6,13,15]. 
 Deli et al. [8] pioneered the establishment of cultures of primary mouse 
cerebral EC with reported sodium fluorescein permeability of 1.812 ± 0.191 × 
10-3 cm/s. Although the reported techniques for isolating mouse BMEC in the 
current study is motivated by the techniques introduced by Deli et al. [8], the 
use of puromycin to obtain pure cultures of BMEC highlights an important 
addition to those techniques [5,14,17]. Puromycin is an antibiotic produced by 
Streptomyces alboniger that inhibits peptidyl transfer in ribosomes. However, 
BMEC can withstand relatively high concentrations of this molecule because 
of the expression of Pgp, which effluxes puromycin out of the cells. Further, 
what distinguishes our method from previous reports using mouse BMEC 
[8,17,26] is the combinatorial addition of biochemical agents (retinoic acid, 
hydrocortisone, cAMP, phosphodiesterase inhibitor, and insulin-transferrin-
sodium selenite) that have been separately shown to induce EC barrier 
tightening in vitro [3,5,10,13,17,27]. Together, the combination of these 
techniques resulted in a model with improved permeability properties 
compared to previous studies. 
 Although the TEER results reported here stand in the lower range 
compared to some previous models based on porcine, bovine, or rat, the 
sodium fluorescein permeability of the non-contact co-cultures on polyester 
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 membranes (3.5 ± 0.1 × 10-6 cm/s) are lower than previous reports [8,10] 
including triple co-cultures between BMEC, astrocytes, and pericytes [12-13]. 
Furthermore, the drug permeability results indicate that this model 
discriminates well between passively and actively transported drugs, and we 
believe this is the first time that a high syngenic correlation coefficient of 0.98 
is achieved. This observation is important because the pharmaceutical 
industry seeks reliable in vitro models for predicting permeability of CNS drugs 
before moving to in vivo testing. Moreover, this model provides the opportunity 
to correlate in vivo and in vitro data obtained from the same species (i.e. 
mouse), while previous reports did such comparisons between different 
species [6,13,26]. 
Although this study revealed no significant difference between the 
properties of BMEC alone and in contact co-culture on neither type of 
membranes, care must be used before making general conclusions about 
whether physical contact is necessary in these models. Properties of the 
transwell membrane, such as thickness, pore size, and pore density play an 
important role in determining whether sufficient physical contact, and therefore 
induction, occurs [9,28]. The pore diameter of the commercial membranes in 
this study (polyester or polycarbonate) was 400 nm, and the observation 
regarding the lack of BMEC induction in contact co-cultures indicate that this 
pore size is not large enough to promote complete extension of astrocyte foot 
processes to the BMEC side, and it appears that this incomplete extension 
blocks the passage of soluble factors (Figure 5.7). This observation is 
consistent with a previous report by Demeuse et al. [9] that indicated astrocyte 
foot processes did not cross membranes through pores of 450 nm, and 
therefore did not induce brain EC. Similar observation was made when 3 µm 
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Figure 5.7 | Astrocyte foot processes clog 400 nm pores of polyester 
membranes. Astrocytes are stained with a cytoplasmic green dye, and as 
shown the foot processes penetrate halfway inside the pores. A red dye is 
added to the other side of the membrane with no cells. The blue shows the 
reflection of the membrane. The width of the image shows the width of the 
membrane. 
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 thick PHOST with 400 nm and 800 nm pores were used. Even though PHOST 
is considerably thinner than commercial membranes, it is possible that 3 µm is 
still too thick to promote physical contact, or 800 nm pores are still too small 
for this thickness. However, the results on different membranes clearly 
indicate that the chemistry of the material and possibly porosity play a major 
role on the physiology of the cultures. It is not clear why the resistance of cells 
are lower on polycarbonate and PHOST versus a commercial polyester 
membrane with the same pore size and total porosity. Further characterization 
is needed to make appropriate conclusions. 
The immunocytochemical characterization in this study leads to an 
interesting observation. The morphology of immunostaining of tight junction 
proteins clearly changes in the non-contact co-cultures compared to BMEC 
alone. This morphological change may correlate with increases at the gene 
expression level, increases at the protein level, or structural changes in the 
proteins such as phosphorylation. Perriere et al. [15] indicated that BMEC co-
cultured with astrocytes have higher occludin, claudin-5, and ZO-1 mRNA 
levels compared to BMEC alone. The Western analysis in this study indicated 
for the first time that this increase in mRNA levels correspond to an increase in 
protein expression levels. However, future characterizations at the protein 
level are needed to investigate possible changes in post-translational 
modifications of these proteins in the presence of astrocytes. 
In vitro BBB models are important research tools to study the structure 
and function of various BBB components under normal and pathological 
conditions. Here, we discuss a model based on murine BMEC with improved 
barrier properties and a high drug permeability correlation coefficient with in 
vivo data. Moreover, this model could serve as a new tool for in vitro studies of 
117 
 118 
BBB in brain cancer, neurodegenerative disorders, and inflammatory events 
and correlation with mouse models of these diseases.  
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 CHAPTER 6 
 
INTRAVENOUS IMMUNOGLOBULIN IMMUNOTHERAPY IN AUTOIMMUNE 
AND NEUROLOGIC DISEASES 
  
6.1 Introduction 
Intravenous immunoglobulin (IVIg) is produced from human plasma derived 
from thousands of healthy donors using a modified Cohn-Oncley cold ethanol 
fractionation process, as well as cation and anion exchange chromatography. 
IVIg contains the entire range of natural antibodies present in normal plasma 
and has been used in the treatment of primary and secondary antibody 
deficiencies for over 50 years [1]. IVIg was first demonstrated to be effective in 
treating an autoimmune disorder, idiopathic thrombosytopenic purpura, in 
1981 [2,3,4]. Since then, IVIg has been established to be effective in the 
treatment of the Guillain-Barre syndrome, chronic inflammatory demyelinating 
polyneuropathy, myasthenia gravis, corticosteroid-resistant dermatomyositis, 
Kawasaki’s syndrome, and in the prevention of graft-versus-host disease in 
recipients of allogenic bone marrow transplants [5]. Benefits of IVIg have also 
been reported in many other autoimmune and systemic inflammatory 
conditions [6].  
 The success of IVIg immunotherapy in the treatment of autoimmune 
diseases has promoted its use for the treatment of neurologic disorders, 
including Alzheimer’s disease [5-9]. In contrast to many autoimmune disorders 
where the affected cells are virtually bathed in high concentrations of infused 
IgG, the access of IVIg to the central nervous system (CNS) is severely 
restricted by the blood-brain barrier (BBB) [10]. However, several studies have 
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 indicated that cerebrospinal fluid (CSF) IgG concentration increases two-fold 
following a high-dose infusion of IVIg, corresponding to a five-fold IgG 
increase in the serum [5]. What remains unclear is whether IVIg molecules 
interact directly with the proteins in the CSF. This review looks at the 
components of IVIg along with its known mechanisms of action in the 
treatment of autoimmune diseases. It further reviews preliminary proteomics 
approaches to identify possible interactions between IVIg and CSF.  
 
6.2 Components of IVIg 
Commercial preparations of IVIg contain intact IgG molecules with a 
distribution of IgG subclasses corresponding to that in normal human serum. 
Most preparations contain traces of IgA and IgM. IVIg also contains trace 
amounts of soluble CD4, CD8, and HLA (human leukocyte antigen) molecules 
and certain cytokines [11-12]. The half-life of infused IVIg in an immune-
competent person is three weeks. 
 Because IVIg consists of polyclonal IgG, both polyreactive natural 
antibodies as well as antibodies with specificities for allotypic antigens are 
present in it. These sources of IgGs have been suggested to contribute to 
IVIg’s efficacy through neutralization of various inflammatory components, 
including pathogenic antibodies [13-14]. However, most experiments have 
shown that the active component of IVIg lies within the Fc domain-containing 
fractions rather than the F(ab)2 fractions, implicating Fc receptor engagement 
rather than neutralization mechanisms. 
 Natural antibodies are more polyreactive than immune antibodies 
because they can often bind to different antigens [15]. Natural antibodies can 
also recognize and be recognized by other autoantibodies in the same person. 
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 The high level of natural antibodies in IVIg, makes a considerable fraction of it 
capable of interacting with idiotypes to form dimers or multimers. The content 
of such dimers increases with the number of donors in the pool [16]. The 
formation of idiotype-idiotype dimers may account for some of the clinical 
effects of IVIg.  
 
6.3 Mechanisms of Action of IVIg 
6.3.1 Fc Receptor Mediated Effects 
Fc receptors (FcR) bind the Fc region of the immunoglobulins. Fcγ receptors 
(FcγR) bind the Fc region of only the γ subclass. The main mechanism of 
action of IVIg in autoantibody-mediated cytopenias is FcγR blockade on 
macrophages [17-18], which leads to the deactivation of phagocytes and 
lymphocytes. In inflammatory neurological disorders IVIg has an anti-
demyelination effect, resulting from FcR blockade. IVIg is believed to prevent 
the phagocytosis of antigen bearing target cells. 
 IVIg has been found to affect antibody kinetics through the neonatal Fc 
receptor (FcRn) blockade. FcRn is a protective transport receptor that 
prevents the catabolism of IgG molecules. Generally, IgG molecules that enter 
the cell bind maximally to FcRn, which protects them from lysosomal 
degradation [19]. When IVIg blocks FcRn receptors, IgG catabolism is 
increased and the concentration of pathogenic autoantibodies are decreased. 
 
6.3.2 Anti-Idiotypic Effects 
IVIg has been found to contain anti-idiotypic antibodies against autoantibodies 
(i.e. idiotypes). Examples of such autoantibodies include anti-DNA, anti-
phospholipids, and anti-acetylcholine receptor. Anti-idiotypic antibodies in IVIg 
125 
 bind and neutralize the autoantibodies and moreover have the ability to 
modulate the immune system by suppressing antibody production [5]. 
However, IVIg does not contain anti-idiotypic antibodies against rare auto-
antibodies. 
 
6.3.3 Effects on Complement Proteins 
The complement system is a complex cascade, which ultimately results in an 
inflammatory response. One of the potent anti-inflammatory effects of IVIg lies 
within the ability of the Fc region of the IgGs to interact with complement 
proteins in the plasma [1]. The anti-inflammatory effects of IVIg have been 
demonstrated is several autoimmune diseases, including dermatomyositis and 
Kawasaki syndrome. In an in vitro study, sera of dermatomyositis patients 
were treated with IVIg and as a consequence a significant decrease in C3 
uptake was observed [20]. This observation is consistent with the idea that 
IVIg withholds complement-mediated tissue damage by preventing the 
deposition of complement proteins on target surfaces. 
 
6.3.4 Effects on the Cytokine Network 
One of the most significant disease-modifying mechanisms of IVIg is the 
regulation of the immune system by altering cytokine levels. IVIg has been 
found to reduce the inflammatory response via natural antibodies against 
specific cytokines, cytokine antagonists, and cytokine receptors [21]. Natural 
antibodies against proinflammatory cytokines, interleukin (IL)-1, tumor 
necrosis factor (TNF)-α, and IL-6 are examples of such antibodies. IVIg 
contains cytokines, which may represent the cytokines existing in normal 
human plasma [21]. Therefore, IVIg’s cytokine rebalancing ability is of great 
126 
 importance in conditions associated with cytokine deregulation, such as 
autoimmune diseases, cancer, and inflammation. IVIg also exerts its anti-
inflammatory effects by regulating the production, release, and function of 
proinflammatory cytokines. IVIg was found to downregulate the production of 
proinflammatory cytokines in vitro in mitogen-stimulated peripheral blood 
mono-nuclear cell (PBMC) cultures. These proinflammatory cytokines include 
IL-2, IL-3, IL-4, and IL-5. 
 
6.4 Protein Targets of IVIg in the Cerebrospinal Fluid 
Experimental evidence of the possible interactions between IVIg and CSF, as 
well as the underlying mechanisms of interaction is non-existent. The 
subsequent section in this chapter provides examples of possible proteomics 
approaches that may be utilized to identify some of these interactions, 
highlighting the experimental results as well as how they fit within the context 
of known disease-modifying effects of IVIg. 
 
6.4.1 Immunoprecipitation with Magnetic Beads 
Immunoprecipitation (IP) is a technique by which a target protein or antigen is 
precipitated from a solution using an antibody specific for that target. IP with 
magnetic beads (i.e. Dynabeads®) can be utilized to identify possible proteins 
in CSF that interact with IVIg, as shown in Figure 6.1. Briefly, IVIg is 
immobilized on Dynabeads® and then CSF is flowed through it. After elution, 
samples are resolved by SDS-PAGE.  
The main source of complication in this analysis is the presence of 
antibodies in the CSF. The endogenous CSF antibodies may bind free beads 
(i.e. beads that have not bound IVIg) and thus a CSF only control is needed to 
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Figure 6.1 | Immunoprecipitation of CSF with Dynabeads® coupled 
with IVIg. IVIg was immobilized on two different Dynabeads: Protein G 
(top) and Protein A (bottom). Both Dynabeads have strong affinity for IgG, 
but Protein A has a better affinity for IgA and IgM compared to Protein G. 
First three lanes from left on both gels correspond to the protein ladder and 
raw samples of IVIg and CSF. Lanes 1-3 correspond to beads+IVIg+CSF, 
beads+CSF (control), and beads+IVIg (control) respectively. Lanes 1S-3S 
correspond to the flow-through of samples 1-3 respectively to monitor the 
efficiency of binding. A protein band that appears in lane 1, but not in lanes 
2 and 3 would be of interest.  
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 analyze the results properly.  Also, because the elution will contain molecules 
present in the IVIg, an IVIg only control is needed to subtract these molecules 
from the final co-immunoprecipitant. Figure 6.1 exemplifies these controls. As 
shown in the figure, protein bands corresponding to elution of IVIg plus CSF 
look similar to IVIg alone, and CSF alone controls, which makes it difficult to 
identify possible interacting partners or complexes. Using two-dimensional gel 
electrophoresis (2DE) to resolve the IP elution may serve as a more sensitive 
technique to analyze such complex mixtures. 
 
6.4.2 One-Dimensional Gel Electrophoresis and Western Blot 
As an alternative approach to IP, CSF can be resolved by one-dimensional 
SDS-PAGE and immunoblotted against IVIg. Membranes are probed with IVIg 
as a primary antibody followed by alkaline phosphatase labeled anti-human 
IgG, IgM, or IgA as a secondary antibody. Bound antibodies are then detected 
using an enhanced chemi-flourescence substrate. Figure 6.2 shows an 
example of such blots probed with anti-human IgG (panel A), IgM (panel B), 
and IgA (panel C).  
Based on the results from the secondary antibody only control blots, it 
appears that CSF proteins themselves interact directly with the secondary 
antibodies. Therefore, it is difficult to deduce whether the protein bands on 
blots probed with IVIg are a results of interaction between IVIg and the 
secondary antibody, or CSF and the secondary antibody. Only two bands, one 
around 14 kD in panel A, and the other one around 66 kD in panel B may be 
indicative of possible interactive partners between IVIg and CSF because 
none appear on the secondary antibody only control blot. These bands can be 
further cut out of the gel and analyzed using mass spectrometry, however, 
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Figure 6.2 | Reactivity of IVIg with CSF using one-dimensional 
western blot. CSF was resolved by 1D SDS-PAGE and immunoblotted. 
Membranes were probed with three different dilutions of IVIg (1:1k, 1:2k, 
1:3k) as the primary antibody followed by anti-human IgG (A), IgM (B), 
and IgA (C) as the secondary antibody. For each panel, the secondary 
antibody control blot is located on the right hand side. In panels A and B, 
only one band (arrow) appears on the IVIg plus secondary antibody, but 
not on the secondary antibody control blot. These bands may 
correspond to proteins in the CSF that bind IgGs or IgMs in IVIg. 
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 because 1D gels are not capable of resolving a high protein content sample, 
2DE may again serve as a better technology for this analysis. 
 
6.4.3 Two-Dimensional Gel Electrophoresis and Western Blot 
2DE permits high resolution separation of individual proteins from complex 
mixtures in two orthogonal dimensions. The sequential use of both separations 
significantly expands the resolving power of 2DE over 1D gels, with a potential 
to resolve as many as 2000-5000 proteins within one sample. Comprehensive 
2DE protein maps have been published for several samples related to 
neurological disorders, including human CSF, Plasma, and brain [22-23]. 
Similar to the techniques introduced in the previous section, CSF can 
be resolved by 2DE and immunoblotted. Membranes are then probed with IVIg 
followed by anti-human IgG, IgM, or IgA. Bound secondary antibodies are then 
detected using an enhanced chemi-flourescence substrate and imaged. The 
blots are then stained using a total protein stain to enable spot identification. 
Figure 6.3 shows an example of such blots. Panel A in this image shows a 
clear example of anti-human IgGs binding to the endogenous 
immunoglobluins (or possibly other proteins) in the CSF, in the secondary 
control blot. However, these interactions seem to be blocked when IVIg is 
used as the primary antibody. In other words, bound IVIg prevents the binding 
of the secondary antibody. Similar effects are not observed when IgM or IgA is 
used as the secondary antibody. While these results are preliminary, they can 
provide hints on the possible interactions between the CSF and IVIg. The 
following section provides an overview of how these results fit within the 
context of the immunology network theory, and of possible disease-modifying 
effects of IVIg in neurologic disorders. 
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Figure 6.3 | Reactivity of IVIg with CSF using two-dimensional 
western blot. CSF was resolved by 2-D gel electrophoresis and 
immunoblotted. Membranes were probed with 1:1k dilution of IVIg as the 
primary antibody followed by anti-human IgG (A), IgM (B), and IgA (C) as 
the secondary antibody. Panel (A) also shows the image of a stained 2-D 
CSF gel on the far right for spot identification. Panel (A) shows that anti-
human IgG is unable to bind endogenous immunoglobulins in the CSF in 
the presence of IVIg. Similar effect is not observed in the other panels. 
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 6.5 Idiotypic Network Theory in Autoimmunity 
In 1974, Jerne [24] proposed that the immune response might be regulated via 
the unique antigenic determinants of Ig variable regions (i.e. idiotypes). This 
hypothesis predicts that the idiotypic determinants of each antibody molecule 
would be complemented by those of another, creating an idiotypic network 
through which Ig expression might be controlled. A wide array of experiments, 
including immunization with anti-idiotype antibodies as a vaccine against 
cancer [25], have strengthened Jerne’s hypothesis. 
 The dogma of idiotypic network theory is that an antigen generates 
antibodies whose serologically unique structure (i.e. idiotype) results in the 
production of anti-idiotypic antibodies. The original antibody is designated Ab1, 
and the anti-idiotypic antibody Ab2. The Ab2 antibodies recognize the antigen-
binding site of Ab1, and therefore share a structural similarity with the original 
antigen. The cascade then repeats with the generation of anti-anti-idiotypic 
antibodies (Ab3) that recognizes Ab2 and so on (Figure 6.4) [24,26-29]. The 
end result is the production of a chain of autoantibodies that recognize each 
other and may modulate the immune system by stimulating or suppressing it. 
However, it is not exactly clear how far this cascade continues and what 
triggers the body to prefer one pathway over another. This network theory has 
been harnessed for preventive immunization as well as for therapeutic 
purposes and it was proposed that the idiotypic network may be involved in 
the pathogenesis of autoimmune diseases [28]. 
 In human autoimmune diseases, remission or recovery may be 
associated with the presence of anti-idiotypic antibodies directed against the 
patient’s autoantibodies in the plasma. Anti-idiotypic antibodies against 
autoantibodies have been found in patients with Systemic Lupus  
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Figure 6.4 | Network of antibodies. (a) According to Jerne’s theory [24], 
immunization with an antigen may lead to the generation of not only Ab1, but 
also the anti-idiotypic antibodies. (b) A unique structure (idiotype) in the 
framework of Ab1 can trigger the idiotypic network. This figure is reprinted by 
permission from Macmillan Publishers Ltd: [Nature Medicine] (26), © (2004). 
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 Erythematosus (SLE) [30-31], myasthenia gravis [32], autoimmune thyroiditis 
[33], and polyneuropathy associated with gammopathy [34]. Intravenous 
infusion of IgG prepared from large pools of normal donors has resulted in 
clinical improvements and decrease in autoantibody titer in several organ-
specific autoimmune diseases [35-37]. In this context, it is believed that IVIg 
interferes with the binding of autoantibodies to their respective antigens. 
As mentioned previously, treatment of neurologic disorders with IVIg 
has indicated that CSF IgG concentration increases two-fold corresponding to 
a five-fold increase in the serum [5]. This increase is reversed when IVIg 
treatment is stopped. Experimental evidence of whether this increased 
concentration of antibody (i.e. anti-idiotypes) interferes with binding of 
autoantibodies, or antibodies that initiate inflammatory, or complement 
cascades in the CSF is non-existant, but experimental techniques outlined in 
the previous section may be useful in addressing this issue. For example, the 
2D western analyses outlined above, provide evidence that IVIg can bind 
endogenous CSF antibodies or proteins in such a way that these molecules 
are no longer available to bind anti-human IgGs. While it is still unclear how 
this blockage contributes to the disease-modifying effects of IVIg in neurologic 
disorders, the phenomenon itself fits well within the context of the anti-idiotype 
network theory and known anti-idiotypic effects of IVIg.  
According to a previously established 2DE CSF map [38], the majority 
of the proteins that appear in the region highlighted by arrows in Figure 6.3 are 
immunoglobulins. A preliminary hypothesis based on the 2D westerns is that 
the binding of IVIg to endogenous CSF immunolgobulins and possibly their 
neutralization alleviates pathologic symptoms. The disease-modifying effects 
may be a primary result of this neutralization, or there may be other cascades 
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 that are affected by this neutralization (i.e. complement and inflammatory 
cascades) that further result in disease modification. However, other proteins 
such as plasminogen, gelsolin, and complement component 3 (C3) also 
appear in the same region. Both plasminogen and C3 have been previously 
implicated as a diagnostic biomarker of AD [39]. Moreover, the concentration 
of C3 decreases in Alzheimer’s patients after six months of IVIg 
immunotherapy [Chapter 8]. Thus, depending on what panel of proteins or 
antibodies in the CSF are involved in interacting with IVIg, a more detailed 
disease-modifying mechanism can be established. 
 
6.6 Conclusion 
The success of intravenous immunoglobulin therapy in the treatment of 
autoimmune diseases has promoted its use for the treatment of neurological 
disorders, including Alzheimer’s disease. Although the access of IVIg to the 
central nervous system is restricted by the blood-brain barrier, experimental 
evidence suggests entry of IgG into the cerebrospinal fluid. However, what 
remains unclear is how the immunoglobulins interact with other proteins in the 
CSF (if any) and whether this interaction is responsible for disease-modifying 
effects. This chapter provided a review on components of IVIg, its known 
mechanisms of action with respect to autoimmune diseases, as well as 
possible proteomics approaches that may be utilized to identify the protein 
targets of IVIg in CSF. In particular, 2DE coupled with western analysis seems 
to be a promising approach to understand these mechanisms. 
 
 
 
139 
 6.7 Supplemental Methods 
6.7.1 Immunoprecipitation with Dynabeads® 
Immunoprecipitation kit-Dynabeads® Protein A and G were purchased from 
Invitrogen (Carlsbad, CA, USA) and samples were prepared following the 
manufacturer’s protocol. Briefly, 6 mg of dynabeads was incubated with 10% 
Gammagard liquid (corresponding to 40 µg of protein in IVIg) (Baxter 
Healthcare Corporation, Westlake Village, CA, USA) on a vortex for 10 
minutes at room temperature. After collection of the flow-through and a single 
washing step, 233 µg of protein in CSF was added to the IVIg-bound 
dynabeads on vortex for 60 minutes at room temperature. After collecting the 
flow-through, CSF bound to IVIg was washed three times and eluted from the 
beads and mixed with Laemmli sample buffer. 15 µL of protein sample was 
resolved by SDS-PAGE (12% w/v) using Tris-HCl. The separated proteins 
were stained with SYPRO Ruby Protein Gel Stain (Molecular Probes), and de-
stained for 24 hours in a solution of 10% methanol and 7% acetic acid. The gel 
was scanned on a FLA-3000 Fluorescent Image Analyzer (Fujifilm Company). 
 Control samples consisted of 2 µg of protein in 10% Gammagard, 7 µg 
of protein in CSF, 40 µg of protein in 10% Gammagard bound to dynabeads, 
and 233 µg of protein in CSF bound to dynabeads.  
 
6.7.2 One-Dimensional Western Blot 
Laemmli sample buffer was mixed with 7 µg of CSF and 15 µL of samples was 
resolved by SDS-PAGE (12% w/v) using Tris-HCl and immunoblotted. All 
subsequent steps were done at room temperature. Membranes were blocked 
in 3% non-fat dry milk for one hour and then probed with 10% as is or dialyzed 
Gammagard at 100 µg/mL, 50 µg/mL, or 33.3 µg/mL for one hour. Following 
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 washing steps, the membranes were incubated with alkaline phosphatase 
conjugated goat anti-human IgG (A3150, Sigma), or IgM (A3275, Sigma), or 
IgA (A3400, Sigma) at 1:30,000 dilution. Bound antibodies were detected 
using an ECF substrate following the manufacturer’s instructions and imaged 
using a FLA-3000 Fujifilm scanner. Dialyzed IVIg was prepared using a 3.5k 
Slide-A-Lyzer (Thermo Fisher) in a solution of acetic acid at pH4 [40-41]. 
 
6.7.3 Two-Dimensional Western Blot 
Briefly, 300 μL of CSF (containing approximately 120 µg of protein) were 
precipitated using ice-cold ethanol. The resulting protein pellet was dissolved 
in a solution of 9 M urea (Bio-Rad), 2% 2-mercaptoethanol (J.T. Baker), 2% 
IGEPAL (Sigma), and 0.25% carrier ampholytes (Bio-Rad). The sample was 
then loaded directly into a 18 cm, 3-10 nonlinear immobilized pH gradient 
(IPG) isoelectric focusing gel (GE Healthcare). A Protean IEF unit (Bio-Rad) 
was used to perform isoelectric focusing at 20 ºC for a total of 100 kVh. The 
IPG gels were equilibrated in solutions containing dithiothreitol (Bio-Rad) and 
subsequently iodoacetamide (Fluka) for reduction and alkylation of the 
focused proteins. Polyacrylamide gel electrophoresis was performed using 12-
15% T gradient slab gels. 
 The gels were then immunoblotted and all subsequent steps were done 
at room temperature. Membranes were blocked in 3% non-fat dry milk for one 
hour and then probed with 10% as is or dialyzed Gammagard at 100 µg/mL for 
one hour. Following washing steps, the membranes were incubated with 
alkaline phosphatase conjugated goat anti-human IgG (A3150, Sigma), or IgM 
(A3275, Sigma), or IgA (A3400, Sigma) at 1:30,000 dilution. Bound antibodies 
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were detected using an ECF substrate following the manufacturer’s 
instructions and imaged using a FLA-3000 Fujifilm scanner.  
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 CHAPTER 7 
 
PROTEOMIC ANALYSIS OF DIAGNOSTIC BIOMARKERS FOR 
ALZHEIMER’S DISEASE RELATED TO INTRAVENOUS IMMUNOGLOBULIN 
THERAPY 
  
7.1 Preface 
This chapter is adapted from: Shayan, G., Relkin, N., Lee, K. H. 2010. 
Proteomic analysis of diagnostic biomarkers for Alzheimer’s disease related to 
intravenous immunoglobulin therapy. Clinical Chemistry, in preparation. It 
reports on the identification of possible effects of IVIg on diagnostic 
biomarkers of Alzheimer’s disease in a group of eight subjects who underwent 
immunotherapy using a Random Forest classification model. 
 
7.2 Abstract 
Intravenous immunoglobulin (IVIg) therapy has shown promising results in 
treating Alzheimer’s disease (AD). In this study, a Random Forest 
classification model was used to identify possible effects of IVIg on a group of 
eight subjects who underwent immunotherapy. Cerebrospinal fluid (CSF) 
samples from eight AD subjects who underwent IVIg therapy were collected 
before the therapy, after six months of therapy, and after a three months drug 
washout period. Samples were analyzed using two-dimensional gel 
electrophoresis and further studied using a Random Forest classification 
model to identify effects of IVIg on a panel of 23 putative diagnostic AD 
biomarkers previously identified. Six of the eight subjects showed 
improvements with respect to the 23 AD diagnostic biomarkers after six 
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 months of therapy compared to the samples taken before the trial. All subjects 
reverted back to baseline during drug washout. These results are also 
consistent with the clinical observations. The observed improvements in 
subjects during six months of IVIg therapy and the reversion back to baseline 
during drug washout provides preliminary evidence regarding the potential use 
of IVIg as an AD immunotherapy. 
 
7.3 Introduction 
According to recent estimates, as many as 5.3 million Americans are living 
with Alzheimer’s disease (AD) [1]. AD is a progressive, neurodegenerative 
disorder affecting more than five percent of people over the age of 65 and is 
the leading cause of dementia in the elderly [2]. AD is characterized by a 
progressive cognitive decline associated with neurovascular dysfunction, 
accumulation of neurotoxic amlyloid beta (Aβ) on blood vessels and in the 
brain parenchyma, intraneuronal lesions, and neurofibrillar tangles [2]. 
 Active immunization against Aβ in preclinical studies using transgenic 
animal models of AD resulted both in reduction of Aβ in the cerebrospinal fluid 
(CSF) and plaque burden [3-4]. The change in Aβ plaque burden was also 
associated with restored cognitive function in some of these transgenic 
animals [5-6]. Similar results were obtained in animal studies with passive 
immunization using monoclonal antibodies against Aβ [7].  
There is significant interest in the use of passive immunotherapy to 
treat AD. Intravenous immunoglobulin (IVIg) is a pool of human 
immunoglobulins obtained from the blood of thousands of healthy donors that 
has been approved for more than two decades by the United States Food and 
Drug Administration for treatment of immune deficiency disorders and other 
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 indications, but not AD. However, an initial study of IVIg in patients with 
neurologic diseases but not AD suggested that IVIg increased blood anti- Aβ 
antibody levels and fostered Aβ clearance [8].  
 An open label dose-ranging study in moderate AD subjects involved 
IVIg therapy for six months, which was discontinued for three months 
(washout period), and then resumed for another nine months [9]. As a result of 
this therapy, CSF Aβ decreased significantly after six months of therapy, 
returned to baseline after IVIg washout and decreased again after IVIg was re-
administered. Mini-Mental State Examination (MMSE) scores increased an 
average of 2.5 points after six months, returned to baseline during washout, 
and remained stable during subsequent IVIg therapy. An important question is 
whether other molecular changes could be identified in the longitudinal CSF 
samples that were collected as part of this study. 
 Previously, a panel of 23 putative diagnostic AD biomarkers was 
identified and validated using proteomic analysis [10]. The proteins were 
separated using two-dimensional gel electrophoresis and the resulting pattern 
of protein expression was analyzed using the Random Forest (RF) multivariate 
statistical method. Here, CSF samples collected from AD subjects undergoing 
IVIg immunotherapy [9] is analyzed to characterize any potential response of 
the 23 biomarkers. CSF samples taken before the therapy, after six months of 
therapy, and after a three months IVIg washout were used for this study. The 
gels were analyzed using a previously described classification model [10] to 
identify possible effects of IVIg therapy on the panel of 23 AD biomarkers. 
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 7.4 Materials and Methods 
7.4.1 Cerebrospinal Fluid Samples 
Lumbar CSF samples were obtained from eight subjects enrolled in a phase I 
clinical trial of IVIg therapy for the treatment of AD at Weill Cornell Medical 
College [9]. All subjects have been diagnosed with probable AD based on 
NINCDS-ADRDA criteria [11]. The subjects have been randomly assigned to 
one of four different dosing regimens: 0.4 g/kg every two weeks, 0.4 g/kg 
every week, 1 g/kg every two weeks, and 2 g/kg every month, as described 
previously [9]. Serial lumbar CSF samples taken before IVIg therapy, after six 
months of therapy, and after three months of IVIg washout were analyzed for 
this study. This information is summarized in Table 7.1. CSF samples were 
also collected at an interim time point within the first 6 months of therapy. For 
the washout period, a CSF sample from subject #5 was not available. The 
CSF samples and their corresponding 2DE gels appeared free from blood 
contamination. Samples were stored at -70°C until used. 
 
7.4.2 Two-Dimensional Gel Electrophoresis 
The CSF samples were separated using 2DE. The details of the 2DE protocol 
have been previously published [12]. Briefly, 300 μL of CSF (containing 
approximately 120 µg of protein) were precipitated using ice-cold ethanol. The 
resulting protein pellet was dissolved in a solution of 9 M urea (Bio-Rad), 2% 
2-mercaptoethanol (J.T. Baker), 2% IGEPAL (Sigma), and 0.25% carrier 
ampholytes (Bio-Rad). The sample was then loaded directly into a 18 cm, 3-10 
nonlinear immobilized pH gradient (IPG) isoelectric focusing gel (GE 
Healthcare). A Protean IEF unit (Bio-Rad) was used to perform isoelectric 
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Table 7.1 | Dosing and sample collection information for the eight AD subjects. 
 
Subject 
IVIg 
dose 
(g/kg) 
# weeks 
between 
doses 
Time of lumbar puncture  
(weeks since IVIg started) 
6 months after 
therapy 
Washout 
period 
1 1.0 2 23.85 36.85 
2 0.4 1 25.14 35.71 
3 0.4 2 22.85 34.42 
4 2.0 4 27 40.71 
5 1.0 2 26.42 -- 
6 0.4 1 27.14 41.28 
7 0.4 2 27.14 41.28 
8 2.0 4 27 41.42 
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 focusing at 20 ºC for a total of 100 kVh. The IPG gels were equilibrated in 
solutions containing dithiothreitol (Bio-Rad) and subsequently iodoacetamide 
(Fluka) for reduction and alkylation of the focused proteins. Polyacrylamide gel 
electrophoresis was performed using 12-15%T gradient slab gels. The 
separated proteins were fixed, stained with SYPRO Ruby Protein Gel Stain 
(Molecular Probes), and de-stained for 24 hours in a solution of 10% methanol 
and 7% acetic acid. The gels were scanned on a FLA-3000 Fluorescent Image 
Analyzer (Fujifilm Company). 
The resulting gel images were imported into the Melanie software 
package (Version 4.0, GeneBio). The software was used to auto-detect spots 
that were subsequently manually edited to remove technical artifacts. Each 
sample gel was then matched to a master gel image created by combining the 
spots present in two gels from before the therapy, and two gels from the 
interim time point within the 6 months of thepray. Matching was initially 
performed using the software’s automated matching tool and then checked 
and corrected manually.  
 
7.4.3 Statistical Analysis 
The gels were analyzed using a previously described classification model built 
using a set of AD and non-AD gels with the RF method [10]. The non-AD CSF 
samples included both normal and neurological control subjects. The 
classification model uses the percent volume data from 23 spots previously 
determined to be important in separating CSF 2DE gels from AD and non-AD 
subjects. A forest was built in the R environment and then used to predict the 
classification (AD class or non-AD class) of the IVIg gels. The percent of trees 
classifying the gels as AD or non-AD was recorded. For an IVIg gel, the 
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 greater the percent of trees classifying the sample as AD, the more similar the 
percent volume data of the IVIg sample is to the percent volume data of the 
AD samples used to build the forest. 
 
7.5 Results 
The percent volume data for the 23 proteins previously identified to be useful 
in differentiating AD and non-AD CSF 2DE gels were extracted from the IVIg 
gels and recorded. This data was run through a classification forest built using 
68 CSF 2DE gels (34 AD, 34 non-AD). Based on these 23 spots, all of the IVIg 
gels, corresponding to CSF taken before the therapy, after six months, and 
during washout were classified as AD. A classification of AD indicates that 
over 50% of the trees in the forest classified the sample in the AD category. 
These data are plotted in Figure 7.1. Six of the eight subjects (1-6) received a 
lower AD classification after six months of therapy compared to the samples 
taken before the trial. All of these subjects (except for subject #5, whose CSF 
sample was not available during washout) received a higher AD classification 
during the washout compared to the samples taken during the IVIg therapy. 
 Relkin et al. observed that after six months of IVIg immunotherapy, the 
group’s MMSE scores increased on average by 2.5 points. After IVIg washout, 
MMSE scores declined towards baseline. In the current RF analysis, the lower 
AD predictions during IVIg immunotherapy and the reversion during drug 
washout was consistent with observed MMSE score changes. The correlation 
coefficient between changes in MMSE and AD classification during IVIg 
therapy and drug washout were 0.11 and 0.95, respectively. Figure 7.2, shows 
the AD classification normalized with baseline for all patients to monitor for 
possible dose dependent effects. 
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Figure 7.1 | Fraction of votes for each CSF sample using a previously 
built Random Forest classification model. The patient numbers refer to the 
dosing schedules listed in Table 7.1. 
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Figure 7.2 | Fraction of AD classification normalized with baseline for 
each patient. Patients receiving 1g/kg/2wk and 0.4g/kg/1wk showed a lower 
AD classification during IVIg therapy. Relkin et al. also observed optimum 
changes in MMSE scores in patients who received 1g/kg/2wk of IVIg. 
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 7.6 Discussion 
In this study, CSF samples from AD subjects undergoing IVIg therapy were 
analyzed using two-dimensional gel electrophoresis. The data was studied 
using the previously developed RF classification model to identify longitudinal  
effects of IVIg therapy on the panel of 23 AD diagnostic biomarkers. In the RF 
method, for any sample, the higher the AD prediction for one class (AD or non-
AD), the more similar the sample is to that class. According to this analysis, six 
of the eight AD subjects received a lower AD classification after six months of 
IVIg therapy, and these predictions reverted to baseline after IVIg washout.  
 Relkin et al. [9] reported that the administration of IVIg to the eight 
subjects with moderate AD led to transient, reproducible, and dose dependent 
increases in serum anti-Aβ antibody titers and parallel increases in plasma 
Aβ40 and Aβ42 levels. It was also observed that after six months of IVIg 
immunotherapy, CSF Aβ40 and Aβ42 levels decreased and the group’s 
MMSE scores increased on average by 2.5 points, following a decline towards 
baseline during the drug washout. The consistency between the RF results 
and the MMSE scores suggests the possibility that the panel of 23 previously 
proposed diagnostic biomarkers may reflect disease severity or cognition. 
Here, subjects 1-6 showed a decline in fraction of AD classifications 
during IVIg therapy, while subjects 7-8 did not show a similar response. MMSE 
scores for subject 7 at baseline, after six months of treatment, and after IVIg 
washout were 25, 28, and 24 respectively corresponding to 80%, 84%, and 
79% AD classification (Figure 7.1). MMSE scores for subject 8 at baseline, 
after 6 months of treatment, and after IVIg washout were 20, 20, and 18 
respectively corresponding to 72%, 76%, and 84% AD classification (Figure 
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 7.1). These MMSE scores are also consistent with the RF observations for 
these subjects. 
 The fraction of AD classifications after the washout period shows a 
significant increase from baseline in subjects 2 and 6. The MMSE scores for 
these two subjects, who also received the same dose of IVIg, improved 
significantly during therapy, and was unchanged during the washout period 
[9]. While the majority of the observations related to RF and MMSE scores are 
consistent, the washout results for these two subjects suggests the possibility 
that the 23 diagnostic biomarkers may not accurately reflect MMSE scores in 
all cases. This is also reflected in the poor correlation coefficient between 
MMSE and AD classification changes during IVIg therapy. One possible 
reason is that the RF analysis measures changes in the 23 AD biomarkers, 
and it is possible that disease-modifying effects of IVIg goes beyond the panel 
of 23 AD biomarkers. If true, then the direction of change of the MMSE score 
may not correspond to a similar change in the panel of 23 diagnostic 
biomarkers in all cases. 
 By performing a proteomic and RF statistical analysis, we showed that 
six of the eight subjects who underwent IVIg therapy received lower AD 
classifications with respect to the 23 AD biomarkers after the therapy. These 
results are in agreement with the reported clinical outcomes, and also provide 
an example on how proteomic biomarkers may be useful in assessing 
treatment paradigms for AD. However, additional studies with a larger cohort 
size are necessary to fully correlate the statistical results with clinical 
outcomes. We believe that longitudinal AD CSF studies proposed in the 
context of clinical tools are critically needed and this report is the first such 
study using proteomic biomarkers.  
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 CHAPTER 8 
 
EFFECTS OF INTRAVENOUS IMMUNOGLOBULIN ON CEREBROSPINAL 
FLUID PROTEOME IN ALZHEIMER’S DISEASE 
 
8.1 Preface 
This chapter is adapted from: Shayan, G., Relkin, N., Lee, K. H. 2010. Effects 
of intravenous immunoglobulin on cerebrospinal fluid proteome in Alzheimer’s 
disease. Annals of Neurology, in preparation. It reports on the identification of 
IVIg induced changes in cerebrospinal fluid samples from a group of subjects 
with AD who underwent IVIg therapy. 
 
8.2 Abstract 
Intravenous immunoglobulin (IVIg) therapy has shown promising results in 
treating Alzheimer’s disease (AD). In this study, serial cerebrospinal fluid 
(CSF) samples from a group of subjects with AD who underwent IVIg therapy 
are analyzed to identify IVIg-induced changes. CSF samples from eight AD 
subjects who underwent IVIg therapy were collected before the therapy, after 
six months of therapy, and after a three months drug washout period. Samples 
were analyzed using a gel-based proteomics strategy to identify IVIg-induced 
changes using two different statistical approaches. The first analysis revealed 
sixty nine proteins that showed a considerable and consistent change during 
IVIg treatment. The second analysis identified 25 proteins that changed 
significantly after six months of therapy, and then the change was sustained or 
reversed during the washout period including Ig molecules, gelsolin, 
transferrin, transthyretin and other proteins. The proteins that showed a 
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 significant change during IVIg therapy have been previously implicated in AD. 
This study provides preliminary evidence regarding the potential group of CSF 
proteins that may be implicated in the treatment of AD as well as the potential 
use of IVIg as an AD immunotherapy. 
 
8.3 Introduction 
Alzheimer’s disease (AD) is the leading cause of dementia in the elderly and 
affects over 5.3 million people in the United States [1]. The disease is 
characterized by amnestic type memory impairment and deterioration of 
language skills, all of which progressively worsen over the course of the 
disease [2-4]. Histopathologically, AD is characterized by intracellular tangles 
of tau protein and extracellular plaques that are primarily composed of amyloid 
beta (Aβ) [5].  
Active immunization against Aβ in preclinical studies using transgenic 
animal models of AD resulted both in reduction of Aβ in the cerebrospinal fluid 
(CSF) and plaque burden [3-4]. The change in Aβ plaque burden was also 
associated with restored cognitive function in some of these transgenic 
animals [5-6]. Similar results were obtained in animal studies with passive 
immunization using monoclonal antibodies against Aβ [7]. 
An approach to passive immunization is the use of intravenous 
immunoglobulin (IVIg) therapy. IVIg is a biological product that contains intact 
IgG molecules with a distribution of IgG subclasses equivalent to that in 
normal human serum [8]. After an IVIg infusion of 2 g/kg (a typical dose used 
to treat other neurological diseases) the serum IgG levels are found to 
increase fivefold. The serum levels return to baseline after 21 to 28 days. IgG 
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 levels in the CSF are found to increase two fold over the first 48 hours and 
then return to normal within a week [9]. 
When subjects with various neurological disorders were given IVIg 
infusions, there was a significant increase in anti-Aβ antibodies in both the 
CSF and serum. In the CSF, the total amount of Aβ and the amount of Aβ1-42 
was shown to significantly decrease after the IVIg infusions. In the serum, 
however, the total amount of Aβ significantly increased after the IVIg infusions 
[10]. There are several proposed effects of the anti-Aβ antibodies in AD 
subjects. The first is that the antibodies bind to the aggregated Aβ and recruit 
microglia to phagocytose the aggregates [11]. The second proposed effect 
suggests that the anti-Aβ antibodies provide a peripheral sink for Aβ causing 
the Aβ to leave the CNS and enter the plasma where it is degraded [4,12]. 
Lastly, there is evidence that anti-Aβ antibodies prevent Aβ aggregation and 
may be able to break up already formed aggregates [13-14]. 
Dodel et al. reported results of a pilot study with five AD subjects who 
were given 0.4 g/kg IVIg every four weeks over the course of six months [15]. 
They reported that the CSF concentration of total Aβ decreased by 30% and 
the serum concentration increased by 233%. Based on Mini-Mental State 
Examination (MMSE) scores before and after six months of IVIg treatment, 
none of the five subjects showed any cognitive decline, and several showed 
an improvement [15]. 
In an open label dose-ranging study, moderate AD subjects were 
treated with IVIg for six months, followed by a three months washout period, 
and then resumed treatment for another nine months [16]. As a result of this 
therapy, CSF Aβ decreased significantly after six months of therapy, returned 
to baseline after IVIg washout and decreased again after IVIg was re-
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 administered. MMSE scores increased an average of 2.5 points after six 
months, returned to baseline during washout, and remained stable during 
subsequent IVIg therapy. An analysis of the longitudinal changes in CSF 
protein expression may provide insights into any disease modifying effects of 
IVIg treatment. 
In this report, serial CSF samples collected from AD subjects 
undergoing IVIg immunotherapy [16] are analyzed using two-dimensional gel 
electrophoresis (2DE) to characterize the potential effects of IVIg treatment. 
CSF samples taken before the therapy, after six months of therapy, and after a 
three months IVIg washout were used for this study. Using two separate 
statistical analyses, proteins with significant concentration changes during the 
therapy followed by sustained or reversed changes during the washout were 
identified. These changes identify possible surrogate endpoints of AD therapy 
and give information about the IVIg therapeutic mechanism of action in AD 
subjects. This study is the first to report on the analysis of serial CSF samples 
from subjects to monitor therapy-induced changes in the CSF proteome. 
 
8.4 Materials and Methods 
8.4.1 Cerebrospinal Fluid Samples 
With institution review board approval, lumbar CSF samples were obtained 
from eight subjects enrolled in a phase I clinical trial of IVIg therapy for the 
treatment of AD at Weill Cornell Medical college [16]. All subjects have been 
diagnosed with probable AD based on NINCDS-ADRDA criteria [17]. The 
subjects have been randomly assigned to one of four different dosing 
regimens: 0.4 g/kg every two weeks, 0.4 g/kg every week, 1 g/kg every two 
weeks, and 2 g/kg every month. Serial lumbar CSF samples taken before IVIg 
166 
 therapy (t=0), after six months of therapy (t=6), and after three months of IVIg 
washout (t=9) were analyzed for this study. This information is summarized in 
Table 8.1. CSF samples were also collected at an interim time point within the 
first six months of therapy. For the washout period, a CSF sample from subject 
#5 was not available. The CSF samples and their corresponding 2DE gels 
appeared free from blood contamination. Samples were stored at -70°C until 
used. 
 
8.4.2 Two-Dimensional Gel Electrophoresis 
The CSF samples were separated using 2DE. The details of the 2DE protocol 
have been previously published [18]. Briefly, 300 μL of CSF (containing 
approximately 120 µg of protein) were precipitated using ice-cold ethanol. The 
resulting protein pellet was dissolved in a solution of 9 M urea (Bio-Rad), 2% 
2-mercaptoethanol (J.T. Baker), 2% IGEPAL (Sigma), and 0.25% carrier 
ampholytes (Bio-Rad). The sample was then loaded directly into a 18 cm, 3-10 
nonlinear immobilized pH gradient (IPG) isoelectric focusing gel (GE 
Healthcare). A Protean IEF unit (Bio-Rad) was used to perform isoelectric 
focusing at 20 ºC for a total of 100 kVh. The IPG gels were equilibrated in 
solutions containing dithiothreitol (Bio-Rad) and subsequently iodoacetamide 
(Fluka) for reduction and alkylation of the focused proteins. Polyacrylamide gel 
electrophoresis was performed using 12-15% T gradient slab gels. The 
separated proteins were fixed, stained with SYPRO Ruby Protein Gel Stain 
(Molecular Probes), and de-stained for 24 hours in a solution of 10% methanol 
and 7% acetic acid. The gels were scanned on a FLA-3000 Fluorescent Image 
Analyzer (Fujifilm Company). 
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Table 8.1 | Dosing and sample collection information for the eight AD subjects. 
 
Subject 
IVIg 
dose 
(g/kg) 
# weeks 
between 
doses 
Time of lumbar puncture  
(weeks since IVIg started) 
6 months after 
therapy 
Washout 
period 
1 1.0 2 23.85 36.85 
2 0.4 1 25.14 35.71 
3 0.4 2 22.85 34.42 
4 2.0 4 27 40.71 
5 1.0 2 26.42 -- 
6 0.4 1 27.14 41.28 
7 0.4 2 27.14 41.28 
8 2.0 4 27 41.42 
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 The resulting gel images were imported into the Melanie software 
package (Version 4.0, GeneBio). The software was used to auto-detect spots 
that were subsequently manually corrected to remove technical artifacts. Each 
sample gel was then matched to a master gel image created by combining the 
spots present in two gels from before the therapy, and two gels from the 
interim time point within the six months of therapy. Matching was initially 
performed using the software’s automated matching tool and then checked 
and corrected manually. The percent integrated intensity (percent volume) of 
each matched spot was then exported.  
 
8.4.3 Statistical Analysis 
An initial analysis was performed to identify spots that showed a consistent 
and considerable change in percent volume between the CSF samples 
collected before the IVIg therapy and after six months of therapy. A spot 
percent volume was deemed a consistent change if the same direction of 
change was observed in at least seven of the eight subjects. The change was 
considerable if there was greater than a two-fold change in at least five of the 
subjects.  
 An alternate statistical analysis was carried out using JMP® 7.0 (SAS 
Institute Inc., Cary, NC, USA) [19]. In this analysis, the percent volume data of 
the identified spots on the gels from CSF samples at t=0 and t=6 (from all 
eight subjects) that showed a normal distribution, were fitted to a linear mixed 
model using JMP Restricted Maximum Likelihood (REML) estimation method. 
In the Fit Model function of JMP, percent volume data was chosen as a role 
variable. Time of CSF sample collection, IVIg dose, the crossed interaction 
between time and dose were chosen as model effects. Dose was then nested 
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 within patients and was chosen as the random effect. This analysis identified 
79 proteins with a significant change in percent volume after six months of IVIg 
therapy. None of these spots showed a significant change with respect to 
dose, or the interaction between time and dose. The same statistical analysis 
was then applied to the % volume of the 79 identified proteins in samples 
collected after six months of IVIg therapy (t=6) and the washout period (t=9) 
from all eight subjects (except subject #5). The purpose of this second 
analysis was to identify proteins out of the pool of 79 spots whose percent 
volume changed significantly after IVIg therapy with this change being 
significantly sustained or reversed during drug washout. The global risk was 
fixed at p < 0.05 for all tests. 
 
8.4.4 Protein Identification 
Some of the proteins in the 2DE spots that showed a change in percent 
volume with IVIg therapy were identified with a 2DE CSF map [20]. Other 
spots were identified using tryptic digestion followed by tandem mass 
spectrometry (MS). The details of the digestion and MS analysis protocols 
have been previously published [21]. The MS analysis was done using a 
matrix-assisted laser desorption/ionization tandem time-of-flight MS (MALDI-
TOF/TOF MS, Applied Biosystems). Peptide mass fingerprint data were 
collected in positive ion reflector mode in the range of 900 to 4000 mass to 
charge ratio. Several of the highest intensity non-trypsin peaks were then 
selected for tandem mass spectrometry analysis. The spectra were analyzed 
using GPS Explorer (Version 2.0, Applied Biosystems), which acts as an 
interface between the Oracle database containing raw spectra and a local 
copy of the Mascot search engine (Version 2.0, [22]). The spectral data were 
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 searched against a locally stored copy of the NCBInr human protein database 
[23] using the Mascot search engine. A mass tolerance of 25 ppm was used 
for the peptide mass fingerprint data and 0.2 Da for the tandem mass 
spectrometry data. For a database match to be considered a positive 
identification, a value of p < 0.05 (calculated by GPS Explorer) was required. 
 
8.5 Results 
A typical CSF 2DE gel from samples before the IVIg therapy is shown in 
Figure 8.1. The number of spots on the CSF 2DE gels did not change 
significantly over the course of the IVIg treatment. There were an average of 
1178 +/- 192 spots in the t=0 CSF gels and 1173 +/- 161 spots in the t=6 CSF 
gels. In the initial analysis, 69 spots demonstrated a consistent and 
considerable change in percent volume between the t=0 and the t=6 CSF 
gels. The direction of change for these 69 2DE spots, along with information 
on the protein(s) identified in the spots, is summarized in Table 8.2. All of the 
2DE spots in Table 8.2 (except for spots 6017 and 1378) show a decrease in 
percent volume after IVIg treatment. 
 In the alternate statistical analysis using JMP® 7.0, 79 spots 
demonstrated a significant change in percent volume between the t=0 and the 
t=6 CSF gels. None of these spots showed a significant change with respect 
to dose or the interaction between time and dose. In the pool of 79 spots, only 
25 spots showed a change that was sustained or reversed in the t=9 CSF gels 
compared to the changes between t=0 and t=6 CSF gels. Table 8.3 lists the 
25 proteins with their corresponding p values and the direction of change 
between t=0, t=6, and t=9 CSF gels. 
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Figure 8.1 | 2DE gel of CSF from subject #7 at baseline. Proteins from Table 
8.3 are labeled with their ID number. 
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Table 8.2 | 2DE spots that show a consistent and considerable change in the 
percent volume after six months of IVIg therapy. 
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ID# Protein ID NCBI [33] Accession # 
Observed/ Calculated 
MW (kDa) 
Δ 
t=0 to t=6
2850 α-1-antitrypsin 1942629 52/44.3 - 
2905 α-1-antitrypsin 1942629 51/44.3 - 
2335 α-1-antitrypsin 1942629 48/44.3 - 
5867 α-1-antitrypsin 1942629 18/44.3 - 
6017 α-1-antitrypsin 1942629 16/44.3 + 
1378 α-1-B-glycoprotein 69990 88/51.9 + 
1010 Albumin 113576 105/69.4 - 
1037 Albumin 113576 105/69.4 - 
1593 Albumin 113576 72/69.4 - 
1861 Albumin 113576 64/69.4 - 
6031 Albumin 113576 53/69.4 - 
2172 Albumin 113576 53/69.4 - 
2185 Albumin 113576 51/69.4 - 
5977 Albumin 113576 45/69.4 - 
2863 Albumin 113576 38/69.4 - 
3463 Albumin 113576 27/69.4 - 
3458 Albumin 113576 27/69.4 - 
4354 Albumin 113576 15/69.4 - 
4537 Albumin 113576 14/69.4 - 
3643 Albumin 113576 24/69.4 - 
3481 Albumin 113576 28/69.4 - 
2964 Apolipoprotein E 178853 37/36.2 - 
3048 Apolipoprotein E 178853 35/36.2 - 
5931 Apolipoprotein E 178853 15/36.2 - 
2775 Apolipoprotein J 178855 40/48.8 - 
2976 Apolipoprotein J 178855 34/48.8 - 
1946 α-2-glycoprotein I 4557327 63/38.3 - 
1432 BiP Protein 6470150 88/70.9 - 
1804 Complement Factor B 291922 65/85.5 - 
1133 Contactin 1 28373119 100/112 - 
712 Contactin 2 4827022 128/113 - 
713 Contactin 2 4827022 128/113 - 
3204 Cyclin D-1 483601 32/7.6 - 
3065 EPC-1 1144299 33/40.1 - 
3260 EPC-1 1144299 31/40.1 - 
2179 EPC-1/Albumin 182424 75/69.8 - 
1566 Fibrinogen Alpha 4504165 100/85.7 - 
1168 Gelsolin 4504165 100/85.7 - 
1174 Gelsolin 4504165 100/85.7 - 
1169 Gelsolin 4504165 100/85.7 - 
1177 Gelsolin 4504165 100/85.7 - 
4682 Gelsolin 4504165 80/85.7 - 
1440 Gelsolin 4504165 65/85.7 - 
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Table 8.2 (Continued) 
4682 Gelsolin 4504165 80/85.7 - 
1440 Gelsolin 4504165 65/85.7 - 
1839 Gelsolin 229908 36/25.2 - 
2989 Malate Dehydrogenase 14585855 24/25.7 - 
903 Plasminogen 135807 95/70.0 - 
1272 Prothrombin 553788 80/53.8 - 
1368 Transferrin 553788 80/53.8 - 
1393 Transferrin 553788 44/53.8 - 
2513 Transferrin 339685 19/12.8 - 
4180 Transthyretin 72146 13/54.3 - 
4648 Vitronectin -- 120/-- - 
858 Unknown -- 105/-- - 
1054 Unknown -- 100/-- - 
1231 Unknown -- 80/-- - 
1523 Unknown -- 75/-- - 
5958 Unknown -- 70/-- - 
1559 Unknown -- 65/-- - 
1796 Unknown -- 58/-- - 
2051 Unknown -- 53/-- - 
2545 Unknown -- 41/-- - 
2694 Unknown -- 35/-- - 
3009 Unknown -- 33/-- - 
3249 Unknown -- 27/-- - 
3464 Unknown -- 24/-- - 
3653 Unknown -- 23/-- - 
5919 Unknown -- 23/-- - 
3784 Unknown -- 19/-- - 
4307 Unknown -- 18/-- - 
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Table 8.3 | 2DE spots that show a significant change in percent volume after 
six months of IVIg therapy followed by a sustained or reversed effect during 
washout. Spots are ordered with respect to p values. 
 
ID# Protein ID NCBI [33] 
Accession # 
MW (kDa) Direction of 
Change 
p Value 
2179 EPC-1 1144299 53/40.1 0>6=9 0.0004 
1169 Gelsolin 4504165 100/85.7 0>6=9 0.0005 
2850 α-1 anti-trypsin 1942629 52/44.3 0>6=9 0.0005 
1168 Gelsolin 4504165 100/85.7 0>6=9 0.0013 
2193 Fibrinogen γ 223170 53/46.2 0>6<9 0.0017 
1869 Albumin 113576 63/69.4 0>6<9 0.0028 
2271 Complement Factor H 758073 70/51 0>6<9 0.0029 
3232 Albumin 113576 32/69.4 0>6=9 0.0032 
3260 Unknown -- 30/-- 0>6<9 0.0033 
858 Inter-α trypsin inhibitor Q14624 120/103.3 0>6=9 0.0045 
3384 Kallikrein 6 preprotein 4506155 27/26.9 0<6=9 0.0064 
1177 Gelsolin 4504165 100/85.7 0>6=9 0.0068 
1181 Gelsolin 4504165 100/85.7 0>6=9 0.0068 
1488 Complement component 3 4557385 78/187 0>6<9 0.007 
2858 Albumin 113576 40/69.4 0>6=9 0.0073 
1762 Unknown -- 45/-- 0>6<9 0.0076 
3435 Unknown -- 28/-- 0>6=9 0.0084 
1048 Ig 226787 95/25 0<6>9 0.0089 
1368 Transferrin 553788 85/53.8 0>6<9 0.0094 
3548 Ig light chain 21669471 25/28.2 0<6>9 0.0098 
1975 Albumin 113576 65/69.4 0>6=9 0.015 
3204 Unknown -- 32/-- 0>6<9 0.0167 
1768 Unknown -- 68/-- 0>6<9 0.0174 
5863 Unknown -- 25/-- 0<6=9 0.0198 
4604 Transthyretin 339685 14/12.8 0<6=9 0.0396 
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  Proteins in Table 8.3 can be categorized in two groups based on 
whether their concentration increased (green and black) or decreased (blue 
and red) during six months of therapy. Proteins within each of the above 
categories were further divided in two categories: those showing a sustained 
effect (black and blue) or those showing a reversion (green and red) during 
washout. 
 
8.6 Discussion 
In the initial analysis, several proteins appeared at least four times in Table 
8.2. It is possible for a given protein to appear at multiple positions in a 2DE 
gel because of the presence of isoforms, post translational modifications or 
degradation fragments. The alternate statistical analysis identified 25 spots 
(Table 8.3) with CSF expression changes between t=0 and t=6, and a 
sustained or reversed change during IVIg washout. Besides those spots 
common to both tables (discussed below), Table 8.2 contains proteins linked 
to AD such as ApoE and ApoJ, with the later being recently implicated in AD 
[24-25]. 
 Our analysis of the longitudinal changes in CSF protein expression 
using 2DE has resulted in exciting observations. First, all of the spots with a 
known protein identity in Table 8.3 (with some present in Table 8.2), have 
been previously implicated in AD. Second, the sensitivity of the experiments 
and thus the observed direction of changes for these proteins are consistent 
with previous reports regarding the changes in their concentration in AD. 
Third, two of the proteins, Ig light chain and complement component 3, have 
also been previously implicated as diagnostic biomarkers of AD [25]. For 
discussion, the proteins in Table 8.3 are arranged in two categories: proteins 
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 with an increase in CSF expression after IVIg therapy, and proteins with a 
decrease in expression after therapy, respectively.  
 Ig, Ig light chain, kallikrein 6 preprotein, and transthyretin show elevated 
CSF expression after six months of IVIg therapy. In the case of the 
immunoglobulins, this increase is mitigated during washout which is consistent 
with the nature of immunotherapy and the transport of antibodies into CSF 
after peripheral administration. The increase in CSF expression of kallikrein 6 
and transthyretin after therapy is consistent with previous reports regarding the 
reduced levels of these proteins in the CSF of patients with AD [26-28]. 
Kallikrein 6, a serine protease, is highly expressed in the brain and 
transthyretin has been shown to bind Aβ [26-27]. 
EPC-1,gelsolin, α-1 anti-trypsin, albumin, and inter-α trypsin inhibitor all 
show a decrease in CSF expression after IVIg treatment, with a sustained 
effect during IVIg washout. The decrease in expression of EPC-1, gelsolin, 
and α-1 anti-trypsin is consistent with previous studies showing increased 
expression of these proteins in the brain or CSF of AD patients [29-35]. Inter-
α-trypsin inhibitor, a plasma protease inhibitor, has been shown to be related 
to the pathogenesis of AD, specifically by playing a role in the formation of 
senile plaques and neuronal degradation [36]. 
Fibrinogen γ, transferrin, complement factor H, and complement 
component 3 also show a decrease in CSF expression after IVIg treatment. 
However, this change is reversed after IVIg washout, which may imply that the 
effect of IVIg on these proteins is not as long term as on the proteins 
discussed above. The decrease in expression of fibrinogen, an Aβ binding 
protein, and transferrin is consistent with previous studies showing elevated 
levels of them in the brain or CSF of AD patients [37-39]. With respect to the 
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complement proteins, several studies have indicated that there is a change in 
complement activity in the brains of patients with AD [40], and that some of its 
isoforms are Aβ binding proteins.  
This study is the first to report on the longitudinal analysis of CSF 
samples from a set of clinical trial subjects to monitor therapy-induced 
changes in the CSF proteome. It is also the first study to report on possible 
protein targets of IVIg in CSF of AD subjects. The results suggest that 
changes in the CSF proteome after IVIg therapy can be detected using 2DE 
when analyzed with robust statistical analyses. Thus, a proteomic analysis of 
the CSF may be useful in the search for biomarkers and possible surrogate 
endpoints to monitor a subject’s response to therapy. Although additional 
studies with a larger cohort size are necessary to fully correlate the statistical 
results with clinical outcomes, we believe that longitudinal AD CSF studies 
proposed in the context of therapy-induced changes are critically needed to 
identify diagnostic and/or treatment biomarkers of AD. 
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 CHAPTER 9 
 
CONCLUSIONS AND FUTURE WORK 
  
9.1 Summary of Conclusions 
The first objective of this research was to improve the utility of current in vitro 
blood-brain barrier (BBB) models for molecular transport studies by applying 
biochemical and nanofabrication techniques. Establishing a primary culture of 
brain microvascular endothelial cells (BMEC) is difficult and time intensive and 
therefore as a first attempt, bovine aortic endothelial cells were studied for the 
development of an in vitro BBB model. These cells are available commercially 
and they can be passaged while retaining their characteristic morphology. The 
aortic endothelial cells were co-cultured with primary rat astrocytes and model 
characterization studies including transendothelial electrical resistance 
(TEER), permeability of small molecules, and immunocytochemistry for the 
expression of tight junction proteins revealed that the endothelial cells are not 
an appropriate cell model for an in vitro BBB model. This led to studies to 
isolate BMEC from mouse brain and further co-culture them with primary rat 
astrocytes on commercially available polyester membranes with 400 nm 
pores. The isolation protocol is based on enzymatic digestion followed by 
density centrifugation steps. Moreover, biochemical additives such as 
puromycin, retinoic acid, cAMP, and hydrocortisone were used in a 
combinatorial fashion to ensure culture purity and barrier tightening. In 
contrast to contact co-cultures, the non-contact co-cultures showed astrocytic 
induction effects and produced a 98% drug permeability correlation coefficient 
with in vivo data from mouse. 
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  In an attempt to assess the effects of membrane’s physical parameters 
(chemistry, thickness, and pore size) on the co-cultures, custom 3 µm thick 
membranes based on poly(hydroxy styrene) (PHOST) were nanofabricated 
using electron beam lithography. As a first attempt to establish the lack of 
cytotoxicity, various cell lines were cultured on protein treated nanofabricated 
membranes and their attachment, proliferation, and differentiation were 
confirmed. Primary mouse BMEC and rat astrocytes were then co-cultured on 
membranes with 400 nm and 800 nm pores and model integrity was assessed 
using TEER and small molecule permeability. Once again, in contrast to 
contact co-cultures, the non-contact co-cultures showed astrocytic induction 
effects. These results indicate that astrocyte foot processes do not pass 
through 400 nm or 800 nm pores on a 3 µm thick PHOST membrane and may 
clog the pores to prevent the diffusion of soluble factors. On the other hand, 
the results indicate that the chemistry of the material has a significant effect on 
the physiological response of the cells. 
 The second objective of this research was to couple proteomics and 
statistical approaches to identify therapeutic targets of intravenous 
immunoglobulin (IVIg) in the cerebrospinal fluid (CSF) by analyzing samples 
from subjects with Alzheimer’s disease (AD) who underwent IVIg 
immunotherapy. A detailed review was provided about active components of 
IVIg and its known disease-modifying mechanisms in autoimmune diseases. 
This review was followed by experimental examples of possible proteomics 
techniques, including immunoprecipitation with beads, one-dimensional, and 
two-dimensional westerns that may be utilized to understand how IVIg 
interacts with the CSF proteins in neurodegenerative disorders. Preliminary 
two-dimensional westerns indicated that IVIg may block the recognition of 
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 some endogenous CSF antibodies and/or proteins by anti-human IgG. These 
results were then analyzed within the framework of immunology network 
theory, which concerns the ability of anti-idiotypes in IVIg to block 
autoantibodies and their inflammatory effects in autoimmune diseases. 
 Later, a Random Forest classification model was used to assess the 
potential use of IVIg as an immunotherapy for AD. CSF samples from AD 
subjects were analyzed using two-dimensional gel electrophoresis and further 
studied using a Random Forest classification model to identify effects of IVIg 
on a panel of 23 putative diagnostic AD biomarkers previously identified. The 
majority of the subjects showed improvements with respect to the 23 AD 
diagnostic biomarkers after six months of therapy compared to the samples 
taken before the trial. The observed improvements provide preliminary 
evidence regarding the potential use of IVIg as an AD immunotherapy. 
 Finally, in a separate study, CSF samples from the same group of AD 
subjects were analyzed to identify IVIg-induced changes. CSF samples 
collected at different time points (i.e. before the therapy, after six months of 
therapy, and after a three months drug washout period) were analyzed using a 
gel-based proteomics strategy and two different statistical approaches were 
used to identify IVIg-induced changes. The first analysis revealed sixty nine 
proteins that showed a considerable and consistent change during IVIg 
treatment. The second analysis identified 25 proteins that changed 
significantly after six months of therapy, and then the change was sustained or 
reversed during the washout period including Ig molecules, gelsolin, 
transferrin, transthyretin and other proteins. The proteins that showed a 
significant change during IVIg therapy have been previously implicated in AD 
and their direction of change at different time points is consistent with previous 
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 reports in the literature. This study provides preliminary evidence regarding the 
potential group of CSF proteins that may be implicated in the treatment of AD. 
 
9.2 Recommendations for Future Work 
9.2.1 BMEC and Astrocyte Co-Cultures on Nanofabricated Membrane with 
Larger Pores 
The co-culture results on commercial membranes and nanofabricated PHOST 
indicated that 400 nm or 800 nm pores are too small to promote the extension 
of astrocyte foot processes, and physical contact between the two cell types. 
These pore sizes are appropriate if the membranes are substantially thinner 
[1]. Due to the polymeric nature of PHOST, reducing its thickness from 3 µm 
will not be feasible because mechanical stability will be compromised. 
Therefore, a reasonable option is to employ photolithographic approaches to 
fabricate pores that are larger than 800 nm [2-4]. Although electron beam 
lithography can be used for this purpose, photolithography is more time 
efficient for high-throughput fabrication and is less expensive than electron 
beam lithography. However, this approach requires confirmation of the lack of 
cytotoxicity of the membranes to make sure that photolithography 
development solvents do not adversely affect the lack of cytotoxicity of the 
membranes. Alternatively different commercially available polymers such as 
polycarbonate or polyester may be used for nanofabrication. However, based 
on preliminary results polycarbonate creates translucent membranes which 
may not be suitable for microscopy. 
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 9.2.2 Dynamic In vitro Model of the BBB 
A major disadvantage of the static models of the BBB is the lack of physiologic 
shear stress due to the absence of intraluminal flow. The role played by 
intraluminal shear stress in BMEC differentiation, as well as maintenance and 
induction of a BBB phenotype is well recognized [5-13]. Therefore, it would be 
advantageous to transfer the co-cultures and biochemical techniques 
developed in this research to a dynamic model system.  
 Previous studies have already reported on the development of a 
dynamic in vitro BBB model based on a three-dimensional hollow fiber 
structure that enables co-culturing of EC with glial cells, with the endothelial 
cells exposed to shear stress [14]. However, none of these studies use 
primary brain endothelial cells. This dynamic model consists of variable 
number of hollow polypropylene fibers (capillaries) with trans-capillary pore 
size of 500 – 600 nm, inside a polycarbonate sealed chamber. The porosity of 
the hollow fiber allows gas and nutrient exchange between the two 
compartments but does not permit cells to pass (the wall thickness of each 
capillary is around 300 µm). Both compartments are accessible by ports in the 
circuit connected with a medium reservoir and a pulsatile pump apparatus. 
 Alternatively, microscale cell culture analog (µCCA), also known as 
‘body-on-a-chip’ which is a microfluidic device to recreate various tissue 
environments in the body on a single chip, may be used for creating a dynamic 
BBB model. Brain EC, astrocytes, and possibly other neuronal or non-
neuronal cell types can be cultured in separate chambers on a single chip, 
interconnected by channels mimicking the blood flow pattern [15-16]. 
Furthermore, this microfluidic system can be used for pharmacokinetics 
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 studies of potential BBB drug targets while possibly incorporating other tissues 
in the body. 
 
9.2.3 Understanding the Disease-Modifying Effects of IVIg in AD 
Chapters 6-8 provided background on how proteomics approaches can be 
employed to identify protein targets of IVIg in CSF as well as a list of 
biomarkers that respond to IVIg therapeutically. IVIg is administered 
intravenously and thus some of its components, if not all, may be crossing the 
BBB. The static or dynamic in vitro model of the BBB can be a useful platform 
technology to study the pharmacodynamics of IVIg. Similar to a drug 
permeability study, IVIg may be added to the luminal compartment and the 
protein content of the abluminal compartment may be analyzed at various time 
points using mass spectrometry and compared to a control abluminal 
composition. 
 Chapter 8 provided a list of 25 IVIg induced biomarkers in the CSF of 
AD subjects. A simplified experimental approach to couple these results with 
in vitro data may be to first analyze the expression of these biomarkers in the 
abluminal compartment using ELISA or mass spectrometry. IVIg may then be 
added to the luminal compartment and possible changes in the amount of 
expression of these biomarkers will be studied using proteomics approaches. 
 
9.3 Conclusion 
This project has focused on two areas: development of a new in vitro model of 
the BBB based on a co-culture between primary mouse brain endothelial cells 
and astrocytes coupled with biochemical interventions and nanofabrication 
techniques, and identification of therapeutically relevant protein targets of IVIg 
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in the CSF of AD subjects. The BBB studies provide a comprehensive 
framework on the importance of using primary cultures as well as additional 
biochemical interventions that may be employed to improve barrier properties. 
The static model provides new opportunities to transfer the model components 
into a dynamic system in order to develop a more physiologically-based and 
authentic in vitro model. Furthermore, the studies on nanofabricated materials 
open doors to a more detailed characterization of cellular responses to 
nanopores. The second part of this thesis provides examples on how 
proteomics approaches coupled with advanced statistical modeling can be 
used to identify therapy induced biomarkers in the CSF. While the studies 
were mainly based on gel-based proteomics approaches, newer approaches 
such as shotgun proteomics can be coupled with these techniques to obtain a 
more comprehensive list of biomarkers. Together, these studies have proven 
the utility of proteomics for the diagnosis and treatment of AD, and possibly 
other neurodegenerative disorders.
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